

→ PC10850

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : <b>C12N 15/57, 15/63, 9/64, A61K 38/48, C07K 16/40, C12Q 1/37</b>		<b>A2</b>	(11) International Publication Number: <b>WO 00/53774</b> (43) International Publication Date: 14 September 2000 (14.09.00)
(21) International Application Number: <b>PCT/US00/06237</b> (22) International Filing Date: 8 March 2000 (08.03.00) (30) Priority Data: 09/264,585 8 March 1999 (08.03.99) US (71) Applicant (for all designated States except US): <b>NEUROCRINE BIOSCIENCES, INC. [US/US]; 10555 Science Center Drive, San Diego, CA 92121 (US).</b> (72) Inventors; and (75) Inventors/Applicants (for US only): <b>KELNER, Gregory, S. [US/US]; 725 Muirlands Vista Way, La Jolla, CA 92037 (US). CLARK, Melody [US/US]; 7075 Charmant Drive #20, San Diego, CA 92122 (US). MAKI, Richard, A. [US/US]; 4175-174 Porte de Palmas, San Diego, CA 92122 (US).</b> (74) Agents: <b>CHRISTIANSEN, William, T. et al.; Seed Intellectual Property Law Group PLLC, Suite 6300, 701 Fifth Avenue, Seattle, WA 98104-7092 (US).</b>		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	

Published

Without international search report and to be republished upon receipt of that report.

(54) Title: METALLOPROTEINASES AND METHODS OF USE THEREFOR



(57) Abstract

Novel members of the ADAMTS family of metalloproteinases are provided, along with variants thereof and agents that modulate an activity of such metalloproteinases. The polypeptides and modulating agents may be used, for example, in the prevention and treatment of a variety of conditions associated with undesirable levels of metalloproteinase activity.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## METALLOPROTEINASES AND METHODS OF USE THEREFOR

## TECHNICAL FIELD

5           The present invention relates generally to compositions and methods for the treatment of conditions associated with undesirable levels of metalloproteinase activity. The invention is more particularly related to metalloproteinases and agents that modulate the activity of such metalloproteinases which may be used, for example, for the therapy of diseases characterized by neuroinflammation and/or  
10   neurodegeneration, as well as autoimmune diseases, cancer and inflammation.

## BACKGROUND OF THE INVENTION

          The ADAMs (A Disintegrin and Metalloproteinase Domain) are a family of proteins that have both a metalloproteinase domain and disintegrin domain. The  
15   ADAMs are membrane anchored proteins that contain homology to snake venom metalloproteases (SVMPs) and disintegrins. This family of proteins now contains over 20 members that have a wide variety of important proteolytic and cell fusion functions. ADAM 17/TACE and ADAM 10/Kuz function as proteases that cleave membrane bound tumor necrosis factor (TNF) and the extracellular domain of Notch, respectively.  
20   Other ADAM family members, such as ADAM 1/fertilin  $\alpha$ , are proteolytically processed to remove the metalloprotease domain but retain the disintegrin domain. This protein has been shown to be essential for sperm-egg cell fusion.

          A closely related family called ADAMTS contains a thrombospondin domain in addition to the disintegrin and metalloproteinase domains. ADAMTS-1, for  
25   example, is expressed in association with inflammatory processes and in a cachexigenic colon carcinoma cell line (see Kuno et al., *J. Biol. Chem.* 272:556-562, 1997; Kuno et al., *Genomics* 46:466-471, 1997). This protein appears to be secreted from the cell and subsequently associated with the extracellular matrix (ECM).

          While the function of ADAMTS-1 and many of the ADAM proteins is  
30   not known, it has been shown that ADAM 17 (TACE) processes TNF from the surface of the cell (see Black et al., *Nature* 385:729-733, 1997). ADAM 10 (Kuzbanian) has

also been shown to cleave TNF from the cell surface (Rosendahl et al., *J. Biol. Chem.* 272:24588-24593, 1997). ADAM 10 may be involved in the cleavage of other cell surface proteins as well. In *Drosophila*, ADAM 10 has been reported to cleave the cell surface proteins Notch (Pan and Rubin, *Cell* 90:271-280, 1997) and Delta (Qi et al.,  
5 *Science* 283:91-94, 1999). Based largely on these results it is thought that ADAMs proteases are involved in the cleavage of proteins, including growth factors, cytokines and proteoglycans, from the cell surface.

Metalloproteinase activity has been linked to cancer metastasis. The activity of metalloproteinases can contribute to the development of neurodegeneration  
10 and inflammation as well. In order to develop agents capable of selectively modulating the activity of a metalloproteinase that contributes to a human disease, it is important to identify and characterize additional metalloproteinases, such as members of the ADAMTS family, and agents that modulate an activity of such metalloproteinases. The present invention fulfills this need and further provides other related advantages.

15

#### SUMMARY OF THE INVENTION

Briefly stated, the present invention provides ADAMTS polypeptides, and methods employing such polypeptides. Within certain aspects, isolated polynucleotides that encode an ADAMTS polypeptide are provided. Certain ADAMTS  
20 polynucleotides encode an ADAMTS polypeptide that comprises: (a) at least 50 consecutive amino acid residues of an ADAMTS protein that comprises a sequence recited in any one of SEQ ID NOs:2, 4, 10, 14, 16, 18, 22, 24, 26 or 27; or (b) a variant of any of the foregoing amino acid sequences that differs in one or more substitutions, deletions, additions and/or insertions, wherein substitutions, if any, are present at no  
25 more than 10% of the consecutive residues of the ADAMTS protein. Such polynucleotides may, within certain embodiments, comprise a sequence recited in any one of SEQ ID NOs:1, 3, 9, 13, 15, 17, 21, 23 or 25.

Within related aspects, the present invention provides recombinant expression vectors comprising an ADAMTS polynucleotide, as well as host cells  
30 transformed or transfected with such an expression vector.

The present invention further provides isolated antisense polynucleotides complementary to at least 20 consecutive nucleotides present within an ADAMTS polynucleotide.

Within further aspects, methods are provided for preparing an ADAMTS polypeptide, comprising the steps of: (a) culturing a host cell transformed or transfected with an expression vector comprising a polynucleotide that encodes an ADAMTS polypeptide comprising: (i) at least 50 consecutive amino acid residues of an ADAMTS protein that comprises a sequence recited in any one of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 or 27; or (ii) a variant of any of the foregoing amino acid sequences that differs in one or more substitutions, deletions, additions and/or insertions, wherein substitutions, if any, are present at no more than 10% of the consecutive residues of the ADAMTS protein; wherein the step of culturing is performed under conditions promoting expression of the polynucleotide sequence; and (b) recovering an ADAMTS polypeptide.

The present invention further provides isolated ADAMTS polypeptides comprising: (a) at least 50 consecutive amino acid residues of an ADAMTS protein that comprises a sequence recited in any one of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 or 27; or (b) a variant of any of the foregoing amino acid sequences that differs in one or more substitutions, deletions, additions and/or insertions, wherein substitutions, if any, are present at no more than 10% of the consecutive residues of the ADAMTS protein. Such an ADAMTS polypeptide may have an ADAMTS activity that is not substantially diminished relative to the ADAMTS protein. ADAMTS polypeptide may comprise an amino acid sequence recited in any one of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 or 27.

Within further aspects, the present invention provides pharmaceutical compositions comprising: (a) an ADAMTS polypeptide comprising: (i) at least 50 consecutive amino acid residues of an ADAMTS protein that comprises a sequence recited in any one of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 or 27; or (ii) a variant of any of the foregoing amino acid sequences that differs in one or more substitutions, deletions, additions and/or insertions, wherein substitutions, if any, are

present at no more than 10% of the consecutive residues of the ADAMTS protein; and  
(b) a physiologically acceptable carrier.

Vaccines are also provided, comprising: (a) an ADAMTS polypeptide comprising: (i) at least 50 consecutive amino acid residues of an ADAMTS protein that comprises a sequence recited in any one of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 or 27; or (ii) a variant of any of the foregoing amino acid sequences that differs in one or more substitutions, deletions, additions and/or insertions, wherein substitutions, if any, are present at no more than 10% of the consecutive residues of the ADAMTS protein; and (b) a non-specific immune response enhancer.

Within further aspects, the present invention provides isolated antibodies, or antigen-binding fragments thereof, that specifically bind to an ADAMTS polypeptide comprising a sequence recited in any one of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 or 27.

The present invention further provides methods for screening for agents that modulate ADAMTS protein expression or activity. Within certain such aspects, methods are provided for screening for an agent that modulates ADAMTS protein expression in a cell, comprising: (a) contacting a candidate modulator with a cell expressing an ADAMTS polypeptide, wherein the polypeptide comprises: (i) at least 50 consecutive amino acid residues of an ADAMTS protein that comprises a sequence recited in any one of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 or 27; or (ii) a variant of any of the foregoing amino acid sequences that differs in one or more substitutions, deletions, additions and/or insertions, wherein substitutions, if any, are present at no more than 10% of the consecutive residues of the ADAMTS protein; and (b) subsequently evaluating the effect of the candidate modulator on expression of an ADAMTS mRNA or polypeptide, and therefrom identifying an agent that modulates ADAMTS protein expression in the cell. Similar screens may be performed using a cell comprising an ADAMTS gene promoter operably linked to a reporter gene, and evaluating the effect of a candidate modulator on expression of the reporter gene.

Within further such aspects, methods are provided for screening for an agent that modulates an ADAMTS protein activity, comprising: (a) contacting a

candidate modulator with an ADAMTS polypeptide, comprising: (i) at least 50 consecutive amino acid residues of an ADAMTS protein that comprises a sequence recited in any one of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 or 27; or (ii) a variant of any of the foregoing amino acid sequences that differs in one or more substitutions, deletions, additions and/or insertions, wherein substitutions, if any, are present at no more than 10% of the consecutive residues of the ADAMTS protein; wherein the polypeptide has an ADAMTS activity that is not substantially diminished relative to the ADAMTS protein; and wherein the step of contacting is carried out under conditions and for a time sufficient to allow the candidate modulator to interact with the polypeptide; and (b) subsequently evaluating the effect of the candidate modulator on an ADAMTS activity of the polypeptide, and therefrom identifying an agent that modulates an activity of an ADAMTS protein.

ADAMTS polynucleotides, polypeptides and modulating agents may be used for a variety of therapeutic applications. Within certain aspects, methods are provided herein for inhibiting neuroinflammation and/or neurodegeneration in a patient, comprising administering to a patient an agent that decreases an activity of an ADAMTS protein that comprises a sequence recited in any one of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 or 27. Certain such agents may inhibit expression of an endogenous ADAMTS gene or may bind to an ADAMTS protein.

Within related aspects, methods are provided for treating a patient afflicted with a condition associated with neuroinflammation and/or neurodegeneration, comprising administering to a patient a pharmaceutical composition as described above, and thereby alleviating one or more symptoms of a condition associated with neuroinflammation and/or neurodegeneration. Such conditions include Alzheimer's disease, Parkinson's disease and stroke.

Methods are further provided for treating a patient afflicted with a condition associated with cell proliferation, cell migration, inflammation and/or angiogenesis, comprising administering to a patient a pharmaceutical composition as described above and thereby alleviating one or more symptoms of a condition associated with neuroinflammation and/or neurodegeneration.

Within further aspects, methods are provided for treating a patient afflicted with an invasive tumor, a brain tumor or a brain injury, comprising administering to a patient an agent that decreases expression or activity of an ADAMTS protein that comprises a sequence recited in any one of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 or 27.

Methods are further provided for modulating ADAMTS expression and/or activity in a cell, comprising contacting a cell expressing an ADAMTS polypeptide with an effective amount of an agent that modulates ADAMTS activity, wherein the ADAMTS polypeptide comprises: (i) at least 50 consecutive amino acid residues of an ADAMTS protein that comprises a sequence recited in any one of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 or 27; or (ii) a variant of any of the foregoing amino acid sequences that differs in one or more substitutions, deletions, additions and/or insertions, wherein substitutions, if any, are present at no more than 10% of the consecutive residues of the ADAMTS protein; and thereby modulating ADAMTS expression and/or activity in the cell.

These and other aspects of the present invention will become apparent upon reference to the following detailed description and attached drawings. All references disclosed herein are hereby incorporated by reference in their entirety as if each was incorporated individually.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 presents the sequence of a polynucleotide encoding the representative human metalloproteinase ADAMTS-2 (SEQ ID NO:1).

Figure 2 presents the predicted amino acid sequence of the representative human metalloproteinase ADAMTS-2 (SEQ ID NO:2).

Figures 3A-3B present a partial sequence of a polynucleotide encoding the representative rat metalloproteinase ADAMTS-4 (SEQ ID NO:3).

Figure 4 presents a partial predicted amino acid sequence of the representative rat metalloproteinase ADAMTS-4 (SEQ ID NO:4).



Figures 5A and 5B present the sequence of a polynucleotide encoding the representative human metalloproteinase KIAA0605 (SEQ ID NO:5).

Figure 6 presents the predicted amino acid sequence of the representative human metalloproteinase KIAA0605 (SEQ ID NO:6).

5        Figures 7A and 7B present the sequence of a polynucleotide encoding the representative human metalloproteinase KIAA0366 (SEQ ID NO:7).

Figure 8 presents the predicted amino acid sequence of the representative human metalloproteinase KIAA0366 (SEQ ID NO:8).

10       Figures 9A and 9B present the sequence of a polynucleotide encoding the representative human metalloproteinase ADAMTS-3 (SEQ ID NO:9).

Figure 10 presents the predicted amino acid sequence of the representative human metalloproteinase ADAMTS-3 (SEQ ID NO:10).

Figures 11A and 11B present the sequence of a polynucleotide encoding the representative human metalloproteinase KIAA0688 (SEQ ID NO:11).

15       Figure 12 presents the predicted amino acid sequence of the representative human metalloproteinase KIAA0688 (SEQ ID NO:12).

Figure 13 presents the sequence of a polynucleotide encoding the representative rat metalloproteinase ADAMTS-5 (SEQ ID NO:13).

20       Figure 14 presents the predicted amino acid sequence of the representative rat metalloproteinase ADAMTS-5 (SEQ ID NO:14).

Figure 15 presents the sequence of a polynucleotide encoding the representative human metalloproteinase ADAMTS-4 (SEQ ID NO:15).

Figure 16 presents the predicted amino acid sequence of the representative human metalloproteinase ADAMTS-4 (SEQ ID NO:16).

25       Figures 17A-17G present a sequence alignment of human ADAMTS-1 (SEQ ID NO:28), ADAMTS-2 (SEQ ID NO:2), ADAMTS-3 (SEQ ID NO:10), ADAMTS-4 (SEQ ID NO:4), KIAA0688 (SEQ ID NO:12), KIAA0366 (SEQ ID NO:8) and KIAA0605 (SEQ ID NO:6).

30       Figure 18 presents the sequence of a polynucleotide encoding the representative bovine metalloproteinase ADAMTS-4 (SEQ ID NO:17).

Figure 19 presents the predicted amino acid sequence of the representative bovine metalloproteinase ADAMTS-4 (SEQ ID NO:18).

Figure 20 presents the sequence of a polynucleotide encoding the representative bovine metalloproteinase KIAA0688 (SEQ ID NO:19).

5        Figure 21 presents the predicted amino acid sequence of the representative bovine metalloproteinase KIAA0688 (SEQ ID NO:20).

Figure 22 presents the sequence of a polynucleotide encoding the representative human metalloproteinase ADAMTS-5 (SEQ ID NO:21).

10       Figure 23 presents the predicted amino acid sequence of the representative human metalloproteinase ADAMTS-5 (SEQ ID NO:22).

Figure 24 presents the sequence of a polynucleotide encoding the representative rat metalloproteinase ADAMTS-2 (SEQ ID NO:23).

Figure 25 presents the predicted amino acid sequence of the representative rat metalloproteinase ADAMTS-2 (SEQ ID NO:24).

15       Figure 26 presents the sequence of a polynucleotide encoding the representative rat metalloproteinase ADAMTS-3 (SEQ ID NO:25).

Figure 27 presents the predicted amino acid sequence of the representative rat metalloproteinase ADAMTS-3 (SEQ ID NO:26).

20       Figure 28 is a photograph depicting a coumassie blue-stained gel following electrophoresis of 500 micrograms brevican, previously incubated with and without ADAMTS-4 (TS-4) as indicated.

Figure 29 depicts the amino acid sequence of ADAMTS-9 (SEQ ID NO:27). The predicted signal sequence is underlined. The Zn binding, met turn, TSP 1 motif and TSP-1 like submotifs are shaded. Two potential furin cleavage sites are in parenthesis with the most likely cleavage site shaded. A potential "cysteine switch" amino acid is indicated with a star. The start of each domain is indicated with an arrow.

25       Figures 30A-30C illustrate the comparison of ADAMTS-9 to other ADAMTS family members. In Figure 30A, the domain structure of human ADAMTS 9 is compared to human ADAMTS 1-8, and also with the *C. elegans* GON-1 protein.

30       The pro-domain, metalloprotease domain, disintegrin-like domain, initial TSP type 1

repeat, spacer region, and TSP1 like submotifs are outlined. Figure 30B shows the consensus sequence for Zn binding in the metalloprotease domain (SEQ ID NO:30), along with the Zn binding site for various ADAM and ADAM-TS proteins (SEQ ID Nos: 42-48, 50) that have active metalloprotease domains for comparison to ADAMTS-9 (SEQ ID NO:49). Conserved residues are shaded. Figure 30C is a dendrogram showing the phylogenetic relationship between the protein sequence of the known ADAM-TS human family members and GON-1 from *C. elegans*.

Figure 31 is a photograph illustrating the tissue distribution pattern of ADAMTS-9 in human fetal and adult cDNA. PCR analysis of several human fetal and adult cDNAs was performed using specific primers to ADAMTS 9. Lanes 2 -16 are human adult tissue cDNAs and lanes 17 - 24 are human fetal cDNAs. Lane 25 is a no cDNA control. The expected product size for these ADAMTS 9 primers is 510 bp. The lower panel contains the same cDNA samples used as a template for PCR with G3PDH primers (expected product size is 1 kb).

Figures 32A and 32B illustrate the chromosomal localization of human ADAMTS-9 to 3p14.3-21.1. Figure 32A is a photograph showing the results of FISH analysis in which a genomic ADAMTS 9 probe hybridized to chromosome 3p. Figure 32B shows two ideograms illustrating the chromosomal position of ADAMTS-9 at 3p14.2-14.3. The International System for Human Cytogenetic Nomenclature 1995 was used.

#### DETAILED DESCRIPTION OF THE INVENTION

As noted above, the present invention is generally directed to polypeptides comprising a member of the ADAMTS family of metalloproteinases, or a variant thereof. Such ADAMTS polypeptides are generally characterized by homology to a known ADAMTS protein, and by the presence of one or more of: (a) a disintegrin domain, (b) a zinc-dependent metalloproteinase domain, (c) an ECM domain and/or (d) a thrombospondin type I motif, which may be identified as described herein. The present invention further provides ADAMTS polynucleotides encoding such polypeptides and agents that modulate an activity of such polypeptides. ADAMTS

polypeptides, polynucleotides and/or modulating agents may generally be used for treating conditions associated with undesirable levels of metalloproteinase activity.

#### ADAMTS POLYNUCLEOTIDES

5 Any polynucleotide that encodes an ADAMTS polypeptide as described herein is encompassed by the present invention. Such polynucleotides may be single-stranded (coding or antisense) or double-stranded, and may be DNA (genomic, cDNA or synthetic) or RNA molecules. Additional coding or non-coding sequences may, but need not, be present within a polynucleotide of the present invention, and a  
10 polynucleotide may, but need not, be linked to other molecules and/or support materials.

ADAMTS polynucleotides may comprise a native ADAMTS sequence (*i.e.*, an ADAMTS gene that can be found in an organism that is not genetically modified), or may comprise a variant of such a sequence. Native ADAMTS sequences  
15 encompassed by the present invention include DNA and RNA molecules that comprise a sequence recited in any one of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23 or 25 as well as homologues thereof from other species and other native ADAMTS sequences that may be identified based on homology to a sequence recited herein. Polynucleotide variants may contain one or more substitutions, additions, deletions  
20 and/or insertions such that an ADAMTS activity of the encoded polypeptide is not diminished, relative to a native ADAMTS protein. The effect on an activity of the encoded polypeptide may generally be assessed as described herein. Preferred variants contain nucleotide substitutions, deletions, insertions and/or additions at no more than 30%, preferably at no more than 20% and more preferably at no more than 10%, of the  
25 nucleotide positions. Certain variants are substantially homologous to a native gene, or a portion or complement thereof. Such polynucleotide variants are capable of hybridizing under moderately stringent conditions to a naturally occurring DNA sequence encoding an ADAMTS polypeptide (or a complementary sequence). Suitable moderately stringent conditions include prewashing in a solution of 5 X SSC, 0.5%  
30 SDS, 1.0 mM EDTA (pH 8.0); hybridizing at 50°C-65°C, 5 X SSC, overnight; followed

by washing twice at 65°C for 20 minutes with each of 2X, 0.5X and 0.2X SSC containing 0.1% SDS). Such hybridizing DNA sequences are also within the scope of this invention.

It will be appreciated by those of ordinary skill in the art that, as a result of the degeneracy of the genetic code, there are many nucleotide sequences that encode a polypeptide as described herein. Some of these polynucleotides bear minimal homology to the nucleotide sequence of any native gene. Nonetheless, polynucleotides that vary due to differences in codon usage are specifically contemplated by the present invention.

A portion of a sequence complementary to a coding sequence (*i.e.*, an antisense polynucleotide) may also be used as a probe or to modulate gene expression. Alternatively, an antisense molecule may be designed to hybridize with a control region of a gene (*e.g.*, promoter, enhancer or transcription initiation site), and block transcription of the gene; or to block translation by inhibiting binding of a transcript to ribosomes. Antisense oligonucleotides may be synthesized directly, or cDNA constructs that can be transcribed into antisense RNA may be introduced into cells or tissues to facilitate the production of antisense RNA. Antisense oligonucleotides are preferably at least 20 nucleotides in length, preferably at least 30 nucleotides in length. A portion of a coding sequence or a complementary sequence may also be designed as a probe or primer to detect gene expression. Probes may be labeled by a variety of reporter groups, such as radionuclides and enzymes, and are preferably at least 10 nucleotides in length, more preferably at least 20 nucleotides in length and still more preferably at least 30 nucleotides in length. Primers are preferably 22-30 nucleotides in length.

ADAMTS polynucleotides may be prepared using any of a variety of techniques. For example, an ADAMTS polynucleotide may be amplified from cDNA prepared from cells that express an ADAMTS protein (*e.g.*, microglia, macrophages, myeloid cells, lymphocytes, astrocytes oligodendrocytes, glial cells, neurons, epithelial cells and/or endothelial cells). Such polynucleotides may be amplified via polymerase chain reaction (PCR). For this approach, sequence-specific primers may be designed

based on the sequences provided herein, and may be purchased or synthesized. An amplified portion may then be used to isolate a full length gene from a human genomic DNA library or from a suitable cDNA library, using well known techniques. Alternatively, a full length gene can be constructed from multiple PCR fragments.

5 ADAMTS polynucleotides may also be prepared by synthesizing oligonucleotide components (which may be derived from sequences provided herein), and ligating components together to generate the complete polynucleotide. One other approach is to screen a library with a synthesized oligonucleotide that hybridizes to an ADAMTS gene. Libraries may generally be prepared and screened using methods well known to

10 those of ordinary skill in the art, such as those described in Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratories, Cold Spring Harbor, NY, 1989. It has been found, within the context of the present invention, that ADAMTS genes are expressed in glia. Accordingly, one suitable library is a microglia (e.g., rat) cDNA library. Other libraries that may be employed will be apparent to those

15 of ordinary skill in the art.

As noted above, polynucleotides comprising portions and other variants of native ADAMTS sequences are within the scope of the present invention. Such polynucleotides may generally be prepared by any method known in the art, including chemical synthesis by, for example, solid phase phosphoramidite chemical synthesis.

20 Alternatively, RNA molecules may be generated by *in vitro* or *in vivo* transcription of DNA sequences encoding an ADAMTS polypeptide, provided that the DNA is incorporated into a vector with a suitable RNA polymerase promoter (such as T7 or SP6). Variants may also be generated by mutagenesis or enzymatic digestion of native sequences. Certain polynucleotides may be used to prepare an encoded polypeptide, as

25 described herein. In addition, or alternatively, a polynucleotide may be administered to a patient such that the encoded polypeptide is generated *in vivo*.

Any polynucleotide may be further modified to increase stability *in vivo*. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends; the use of phosphorothioate or 2' O-methyl rather

30 than phosphodiesterase linkages in the backbone; and/or the inclusion of nontraditional

bases such as inosine, queosine and wybutosine, as well as acetyl- methyl-, thio- and other modified forms of adenine, cytidine, guanine, thymine and uridine.

Nucleotide sequences as described herein may be joined to a variety of other nucleotide sequences using established recombinant DNA techniques. For example, a polynucleotide may be cloned into any of a variety of cloning vectors, including plasmids, phagemids, lambda phage derivatives and cosmids. Vectors of particular interest include expression vectors, replication vectors, probe generation vectors and sequencing vectors. In general, a vector will contain an origin of replication functional in at least one organism, convenient restriction endonuclease sites and one or more selectable markers. Other elements will depend upon the desired use, and will be apparent to those of ordinary skill in the art.

Within certain embodiments, polynucleotides may be formulated so as to permit entry into a cell of a mammal, and expression therein. Those of ordinary skill in the art will appreciate that there are many ways to achieve expression of a polynucleotide in a target cell, and any suitable method may be employed. For example, a polynucleotide may be incorporated into a viral vector such as, but not limited to, adenovirus, adeno-associated virus, retrovirus, or vaccinia or other pox virus (*e.g.*, avian pox virus). Techniques for incorporating DNA into such vectors are well known to those of ordinary skill in the art. A retroviral vector may additionally transfer or incorporate a gene for a selectable marker (to aid in the identification or selection of transduced cells) and/or a targeting moiety, such as a gene that encodes a ligand for a receptor on a specific target cell, to render the vector target specific. Targeting may also be accomplished using an antibody, by methods known to those of ordinary skill in the art.

Other formulations for polynucleotides for therapeutic purposes include colloidal dispersion systems, such as macromolecule complexes, nanocapsules, microspheres, beads, and lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes. A preferred colloidal system for use as a delivery vehicle *in vitro* and *in vivo* is a liposome (*i.e.*, an artificial membrane vesicle). The preparation and use of such systems is well known in the art.

## ADAMTS POLYPEPTIDES

As used herein, the term "ADAMTS polypeptide" encompasses amino acid chains of any length. For example, an ADAMTS polypeptide may comprise a full length endogenous (*i.e.*, native) ADAMTS protein. Such an ADAMTS polypeptide may consist entirely of a native ADAMTS sequence, or may contain additional heterologous sequences. Native ADAMTS proteins may generally be identified based on sequence homology to known ADAMTS protein sequences, such as the representative sequences provided herein, particularly within disintegrin, metalloproteinase and/or thrombospondin motifs. In general, a protein is considered to be an ADAMTS protein if at least 20 consecutive amino acid residues, preferably 40 consecutive amino acids, are identical to a known ADAMTS protein. Alternatively, or in addition, an ADAMTS protein may comprise at least 100 consecutive amino acids that are substantially similar to residues within a known ADAMTS metalloproteinase. "Substantial similarity," as used herein, refers to a sequence that is at least 50% identical, and preferably at least 80% identical.

An ADAMTS protein further comprises one or more of: (a) a disintegrin domain, (b) a zinc-dependent metalloproteinase domain and/or (c) a thrombospondin type I motif; and displays at least one, activity characteristic of such a domain or motif. In general a disintegrin domain serves as an integrin binding loop and has a sequence similar to AVN(E/D)CD (SEQ ID NO:29). Disintegrin domains can also contain the sequence RGD. The metalloproteinase domain is based on the presence of an extended catalytic site consensus sequence (HEXXHXXGXXHD; SEQ ID NO:30). It is thought that the three histidines bind the zinc, the glutamic acid is the catalytic base and the glycine allows an important structural turn (Stocker et al., *Protein Science* 4:823-840, 1995). The thrombospondin domain contains the sequence motif CSRTCG (SEQ ID NO:31).

Another domain that may be present within an ADAMTS protein is a domain that binds to the extracellular matrix. This has been referred to as the ECM domain and has the semiconserved sequence FREEQC (SEQ ID NO:32).



In certain embodiments, amino acid residues within a "substantially similar" region may contain primarily or entirely conservative substitutions. A conservative substitution is one in which an amino acid is substituted for another amino acid that has similar properties, such that one skilled in the art of peptide chemistry would expect the secondary structure and hydrophobic nature of the polypeptide to be substantially unchanged. Amino acid substitutions may generally be made on the basis of similarity on polarity, charge, solubility, hydrophobicity, hydrophilicity and/or the amphipathic nature of the residues. For example, negatively charged amino acids include aspartic acid and glutamic acid; positively charged amino acids include lysine and arginine; and amino acids with uncharged polar head groups having similar hydrophilicity values include leucine, isoleucine and valine; glycine and alanine; asparagine and glutamine; and serine, threonine, phenylalanine and tyrosine. Other groups of amino acids that may represent conservative changes include: (1) ala, pro, gly, glu, asp, gln, asn, ser, thr; (2) cys, ser, tyr, thr; (3) val, ile, leu, met, ala, phe; (4) lys, arg, his; and (5) phe, tyr, trp, his.

An ADAMTS polypeptide may comprise a portion of a native ADAMTS protein. Such a portion is preferably at least 20 consecutive amino acid residues in length, more preferably at least 50 consecutive amino acid residues in length. Within certain embodiments, the portion retains an ADAMTS activity that is not substantially diminished relative to the full length ADAMTS protein. Certain ADAMTS polypeptides comprise a sequence recited in any one of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 or 27.

Alternatively, an ADAMTS polypeptide may comprise a variant of an ADAMTS protein or portion thereof. A "variant" is a polypeptide that differs in sequence from a native ADAMTS protein only in substitutions, deletions, insertions and/or additions. Within certain embodiments, substitutions are made (if at all) at no more than 30%, preferably at no more than 20% and more preferably at no more than 10% of residues within a portion of a native ADAMTS protein, as described above. Substitutions are preferably conservative, as described above. Substitutions, deletions and/or amino acid additions may be made at any location(s) in the polypeptide,

provided that the modification does not diminish at least one ADAMTS activity. Thus, a variant may comprise only a portion of a native ADAMTS sequence. In addition, or alternatively, variants may contain additional amino acid sequences (such as, for example, linkers, tags and/or ligands), preferably at the amino and/or carboxy termini. Such sequences may be used, for example, to facilitate purification, detection or cellular uptake of the polypeptide.

Certain variants retain an activity of the native ADAMTS protein. In other words, the variant has a metalloproteinase activity; (2) functions as an integrin ligand (*i.e.*, binds to an integrin), as determined by any standard binding assay; and/or (3) retains a functional thrombospondin motif. Such a variant may have an ADAMTS activity that is not substantially diminished relative to the ADAMTS protein. In other words, the ADAMTS activity of the variant may be enhanced or unchanged, relative to the native protein, or may be diminished by less than 50%, and preferably less than 20%, relative to the native protein.

Also encompassed by the present invention are splice variants of an ADAMTS protein. Such variants may have one or more of the domains described herein deleted, or one or more such domains may be replaced by a domain providing a different function. Such splice variants may be identified using amplification or hybridization techniques described herein.

Dominant negative forms of ADAMTS proteins are also provided. Such forms include fragments and variants of an ADAMTS protein that, when introduced to a cell expressing a native ADAMTS protein, inhibit an activity of the native protein. Inhibition of ADAMTS protein activity may be assessed as described herein.

In general, ADAMTS polypeptides may be prepared using any of a variety of techniques that are well known in the art. For example, polypeptides of the present invention may be prepared by expression of recombinant DNA encoding the polypeptide in cultured host cells. Preferably, the host cells are bacteria, yeast, insect or mammalian cells. The recombinant DNA may be cloned into any expression vector suitable for use within the host cell and transfected into the host cell using techniques well known to those of ordinary skill in the art. An expression vector generally contains

a promoter sequence that is active in the host cell. A tissue specific promoter may also be used, as long as it is activated in the target cell. Preferred promoters express the polypeptide at high levels.

Optionally, the construct may contain an enhancer, a transcription  
5 terminator, a poly(A) signal sequence, a bacterial or mammalian origin of replication and/or a selectable marker, all of which are well known in the art. Enhancer sequences may be included as part of the promoter region used or separately. Transcription terminators are sequences that stop RNA polymerase-mediated transcription. The poly(A) signal may be contained within the termination sequence or incorporated  
10 separately. A selectable marker includes any gene that confers a phenotype on the host cell that allows transformed cells to be identified. Such markers may confer a growth advantage under specified conditions. Suitable selectable markers for bacteria are well known and include resistance genes for ampicillin, kanamycin and tetracycline. Suitable selectable markers for mammalian cells include hygromycin, neomycin, genes  
15 that complement a deficiency in the host (e.g. thymidine kinase and TK<sup>-</sup> cells) and others well known in the art.

ADAMTS polypeptides may be expressed in transfected cells by culturing the cell under conditions promoting expression of the transfected polynucleotide. Appropriate conditions will depend on the specific host cell and  
20 expression vector employed, and will be readily apparent to those of ordinary skill in the art. For commercially available expression vectors, the polypeptide may generally be expressed according to the manufacturer's instructions. Expressed polypeptides of this invention are generally isolated in substantially pure form. Preferably, the polypeptides are isolated to a purity of at least 80% by weight, more preferably to a  
25 purity of at least 95% by weight, and most preferably to a purity of at least 99% by weight. In general, such purification may be achieved using, for example, the standard techniques of ammonium sulfate fractionation, SDS-PAGE electrophoresis, and/or affinity chromatography.

Such techniques may be used to prepare native polypeptides or variants  
30 thereof. For example, variants of a native polypeptide may generally be prepared from

polynucleotide sequences modified via standard mutagenesis techniques, such as oligonucleotide-directed site-specific mutagenesis, and sections of the DNA sequence may be removed to permit preparation of truncated polypeptides. Portions and other variants having fewer than about 100 amino acids, and generally fewer than about 50  
5 amino acids, may also be generated by synthetic means, using techniques well known to those of ordinary skill in the art. For example, such polypeptides may be synthesized using any of the commercially available solid-phase techniques, such as the Merrifield solid-phase synthesis method, where amino acids are sequentially added to a growing amino acid chain. See Merrifield, *J. Am. Chem. Soc.* 85:2149-2146, 1963. Equipment  
10 for automated synthesis of polypeptides is commercially available from suppliers such as Applied BioSystems, Inc. (Foster City, CA), and may be operated according to the manufacturer's instructions.

In general, polypeptides and polynucleotides as described herein are isolated. An "isolated" polypeptide or polynucleotide is one that is removed from its  
15 original environment. For example, a naturally-occurring protein is isolated if it is separated from some or all of the coexisting materials in the natural system. A polynucleotide is considered to be isolated if, for example, it is cloned into a vector that is not a part of the natural environment.

#### 20 EVALUATION OF ADAMTS ACTIVITY

As noted above, native ADAMTS proteins and certain variants thereof possess ADAMTS activity. In other words, such polypeptides (1) possess metalloproteinase activity; (2) are capable of interacting with integrin and/or (3) retain a functional thrombospondin motif. Metalloproteinase activity may generally be  
25 evaluated by combining an ADAMTS polypeptide with a suitable substrate, and detecting proteinase activity using any standard technique (*e.g.*, Western blot analysis). In general, a variant of an ADAMTS protein that contains a metalloproteinase domain is said to retain metalloproteinase activity if it displays metalloproteinase activity that is not substantially diminished relative to the metalloproteinase activity of the native

ADAMTS protein. In other words, such activity may be enhanced, unchanged or diminished by less than 10%, relative to the activity of the native ADAMTS protein.

The ability of an ADAMTS protein variant to interact with integrin may be assessed using standard binding assays to detect interaction with a purified recombinant integrin or a cell expressing one or more integrins, either naturally or as a result of transfection with genes encoding an integrin (*see Almeida et al., Cell 81:1095-1104, 1995; Chen et al., J. Cell Biol. 144:549-561, 1999*). Antibodies against various integrins can also be used to interfere with disintegrin-integrin binding and used to further demonstrate specificity of the interaction. In general, a variant of an ADAMTS protein is said to retain the ability to interact with an integrin if such interaction is not substantially diminished relative to the interaction between a native ADAMTS protein and the integrin. In other words, the level of such an interaction may be enhanced, unchanged or diminished by less than 10%, relative to the activity of the native ADAMTS protein.

Thrombospondins have been shown to function in cell adhesion, cell migration, cell proliferation and angiogenesis. A functional thrombospondin motif may be confirmed based on any assay designed to assess such a function. For examples, an ADAMTS protein may inhibit endothelial cell migration, or may inhibit angiogenesis (*e.g., in a rat cornea model; see Nishimori et al., Oncogene 15:2145-2150, 1997*). Alternatively, a functional thrombospondin motif may be detected using an assay to measure binding to CD36 (*see Dawson et al., J. Cell. Biol. 138:707-717, 1997*). Within any such assay, a variant of an ADAMTS protein is said to have a functional thrombospondin motif if the detected thrombospondin function is not substantially diminished relative to that of the native ADAMTS protein. In other words, the function may be enhanced, unchanged or diminished by less than 10%, relative to that of the native ADAMTS protein.

#### ADAMTS POLYPEPTIDE MODULATING AGENTS

The present invention further provides agents capable of modulating ADAMTS activity. Such agents may function by modulating ADAMTS transcription

or translation, by stabilizing or destabilizing an ADAMTS protein, or by directly inhibiting or enhancing an activity of an ADAMTS protein. Alternatively, an agent may interact with a substrate for the metalloproteinase or with an integrin involved in and interaction with the disintegrin domain of an ADAMTS protein. Preferably, a  
5 modulating agent has a minimum of side effects and is non-toxic. For some applications, agents that can penetrate cells or that are targeted to interstitial spaces are preferred.

Modulating agents include substances that selectively bind to an ADAMTS protein. Such substances include antibodies and antigen-binding fragments  
10 thereof (*e.g.*, F(ab)<sub>2</sub>, Fab, Fv, V<sub>H</sub> or V<sub>K</sub> fragments), as well as single chain antibodies, multimeric monospecific antibodies or fragments thereof and bi- or multi-specific antibodies and fragments thereof. Antibodies that bind to an ADAMTS protein may be polyclonal or monoclonal, and are specific for an ADAMTS polypeptide (*i.e.*, bind to such a peptide detectable within any appropriate binding assay, and do not bind to an  
15 unrelated protein in a similar assay under the same conditions). Preferred antibodies are those antibodies that function as modulating agents to inhibit or block an ADAMTS activity *in vivo*. Antibodies may also be employed within assays for detecting the level of ADAMTS protein within a sample.

Antibodies may be prepared by any of a variety of techniques known to  
20 those of ordinary skill in the art (*see, e.g.*, Harlow and Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory, 1988). In one such technique, an immunogen comprising the polypeptide is initially injected into a suitable animal (*e.g.*, mice, rats, rabbits, sheep and goats), preferably according to a predetermined schedule incorporating one or more booster immunizations, and the animals are bled periodically.  
25 Polyclonal antibodies specific for the polypeptide may then be purified from such antisera by, for example, affinity chromatography using the polypeptide coupled to a suitable solid support.

Monoclonal antibodies may be prepared, for example, using the technique of Kohler and Milstein, *Eur. J. Immunol.* 6:511-519, 1976, and improvements  
30 thereto. Briefly, these methods involve the preparation of immortal cell lines capable of

producing antibodies having the desired specificity (*i.e.*, reactivity with the polypeptide of interest). Such cell lines may be produced, for example, from spleen cells obtained from an animal immunized as described above. The spleen cells are then immortalized by, for example, fusion with a myeloma cell fusion partner, preferably one that is syngeneic with the immunized animal. For example, the spleen cells and myeloma cells may be combined with a nonionic detergent for a few minutes and then plated at low density on a selective medium that supports the growth of hybrid cells, but not myeloma cells. A preferred selection technique uses HAT (hypoxanthine, aminopterin, thymidine) selection. After a sufficient time, usually about 1 to 2 weeks, colonies of hybrids are observed. Single colonies are selected and tested for binding activity against the polypeptide. Hybridomas having high reactivity and specificity are preferred.

Monoclonal antibodies may be isolated from the supernatants of growing hybridoma colonies. In addition, various techniques may be employed to enhance the yield, such as injection of the hybridoma cell line into the peritoneal cavity of a suitable vertebrate host, such as a mouse. Monoclonal antibodies may then be harvested from the ascites fluid or the blood. Contaminants may be removed from the antibodies by conventional techniques, such as chromatography, gel filtration, precipitation, and extraction.

Once a cell line, such as a hybridoma, expressing an antibody that specifically binds to an ADAMTS protein has been obtained, other chimeric antibodies and fragments thereof as described herein may be prepared. Using well known techniques, a cDNA molecule encoding the antibody may be identified.

Other modulating agents include peptides, and nonpeptide mimetics thereof, that specifically interact with one or more regions of an ADAMTS polypeptide. Such agents may generally be identified using any well known binding assay, such as a representative assay provided herein. For example, such modulating agents may be isolated using well known techniques to screen substances from a variety of sources, such as plants, fungi or libraries of chemicals, small molecules or random peptides.

Other modulating agents may function by inhibiting or enhancing transcription or translation of an ADAMTS gene. For example, modulating agents may include antisense polynucleotides (DNA or RNA), which inhibit the transcription of a native ADAMTS protein. cDNA constructs that can be transcribed into antisense RNA may also be introduced into cells of tissues to facilitate the production of antisense RNA. Antisense technology can generally be used to control gene expression through triple-helix formation, which compromises the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors or regulatory molecules (see Gee et al., *In Huber and Carr, Molecular and Immunologic Approaches*, Futura Publishing Co. (Mt. Kisco, NY; 1994). Alternatively, an antisense molecule may be designed to hybridize with a control region of a gene (e.g., promoter, enhancer or transcription initiation site), and block transcription of the gene; or to block translation by inhibiting binding of a transcript to ribosomes. Antisense polynucleotides are generally at least 10 nucleotides in length, more preferably at least 20 nucleotides in length and still more preferably at least 30 nucleotides in length.

Other agents may modulate transcription by interacting with an ADAMTS promoter. Such agents may be identified using standard assays, following isolation of an endogenous ADAMTS gene promoter region. One method for identifying a promoter region uses a PCR-based method to clone unknown genomic DNA sequences adjacent to a known cDNA sequence. This approach may generate a 5' flanking region, which may be subcloned and sequenced using standard methods. Primer extension and/or RNase protection analyses may be used to verify the transcriptional start site deduced from the cDNA.

To define the boundary of the promoter region, putative promoter inserts of varying sizes may be subcloned into a heterologous expression system containing a suitable reporter gene without a promoter or enhancer may be employed. Internal deletion constructs may be generated using unique internal restriction sites or by partial digestion of non-unique restriction sites. Constructs may then be transfected into cells that display high levels of ADAMTS protein expression. In general, the construct with



the minimum 5' flanking region showing the highest level of expression of reporter gene is identified as the promoter.

To evaluate the effect of a candidate agent on ADAMTS gene transcription, a promoter or regulatory element thereof may be operatively linked to a reporter gene. Such a construct may be transfected into a suitable host cell, which may be used to screen, for example, a combinatorial small molecule library. Briefly, cells are incubated with the library (*e.g.*, overnight). Cells are then lysed and the supernatant is analyzed for reporter gene activity according to standard protocols. Compounds that result in a decrease in reporter gene activity are inhibitors of ADAMTS gene transcription.

For modulating agents that act directly on an ADAMTS protein, an initial screen to assess the ability of candidate agents to bind to such a protein may be employed, although such binding is not essential for a modulating agent. For identifying agents that bind to an ADAMTS polypeptide, any of a variety of binding assays may be employed, such as standard affinity techniques and yeast two-hybrid screens. In general, the amount of candidate modulator added in such screens ranges from about 1 pM to 1  $\mu$ M. An antibody or other modulating agent is said to "specifically bind" to an ADAMTS polypeptide if it reacts at a detectable level with such a polypeptide and does not react detectably with unrelated polypeptides. Such antibody binding properties may be assessed using, for example, an ELISA.

Screens for modulating agents that increase the rate of ADAMTS protein synthesis or stabilize ADAMTS protein may be readily performed using well known techniques that detect the level of ADAMTS protein or mRNA. Suitable assays include RNA protection assays, *in situ* hybridization, ELISAs, Northern blots and Western blots. Such assays may generally be performed using standard methods (*see* Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratories, Cold Spring Harbor, NY, 1989). For example, to detect mRNA encoding ADAMTS protein, a nucleic acid probe complementary to all or a portion of an ADAMTS gene sequence may be employed in a Northern blot analysis of mRNA prepared from suitable cells (*e.g.*, brain, lung, heart, spleen, spinal cord, testis, astrocytes or microglia).

To detect ADAMTS protein, a reagent that binds to the protein (typically an antibody) may be employed within an ELISA or Western assay. Following binding, a reporter group suitable for direct or indirect detection of the reagent is employed (*i.e.*, the reporter group may be covalently bound to the reagent or may be bound to a second molecule, such as Protein A, Protein G, immunoglobulin or lectin, which is itself capable of binding to the reagent). Suitable reporter groups include, but are not limited to, enzymes (*e.g.*, horseradish peroxidase), substrates, cofactors, inhibitors, dyes, radionuclides, luminescent groups, fluorescent groups and biotin. Such reporter groups may be used to directly or indirectly detect binding of the reagent to a sample component using standard methods known to those of ordinary skill in the art.

To use such assays for identifying a modulating agent, the level of ADAMTS protein or mRNA is evaluated in cells (*e.g.*, astrocytes or microglia) treated with one or more candidate modulating agents. An increase or decrease in ADAMTS levels may be measured by evaluating ADAMTS mRNA and/or protein in the presence and absence of candidate modulating agent. In general, the amount of candidate modulator added in such screens ranges from about 1 pM to 1  $\mu$ M. A candidate that results in a statistically significant change in the level of ADAMTS mRNA and/or protein is a modulating agent.

Modulating agents that decrease ADAMTS levels generally inhibit ADAMTS activity. To further evaluate the effect on ADAMTS activity, an assay may be performed as described above in the presence and absence of modulating agent. Agents that bind to a substrate of an ADAMTS protein domain may also be identified using such assays. Modulating agents may generally be administered by addition to a cell culture or by the methods described below for *in vivo* administration.

25

#### ADAMTS POLYPEPTIDE AND MODULATING AGENT MODIFICATION AND FORMULATIONS

An ADAMTS polypeptide or modulating agent as described herein may, but need not, be linked to one or more additional molecules. In particular, as discussed below, it may be beneficial for certain applications to link multiple polypeptides and/or modulating agents (which may, but need not, be identical) to a support material, such as

30

a polymeric matrix or a bead or other particle, which may be prepared from a variety of materials including glass, plastic or ceramics. For certain applications, biodegradable support materials are preferred.

Suitable methods for linking an ADAMTS polypeptide or modulating agent to a support material will depend upon the composition of the support and the intended use, and will be readily apparent to those of ordinary skill in the art. Attachment may generally be achieved through noncovalent association, such as adsorption or affinity or, preferably, via covalent attachment (which may be a direct linkage or may be a linkage by way of a cross-linking agent).

It may be beneficial for certain applications to link an ADAMTS polypeptide or modulating agent to a targeting agent to facilitate targeting to one or more specific tissues. As used herein, a "targeting agent," may be any substance (such as a compound or cell) that, when linked to a polypeptide or modulating agent enhances the transport of the polypeptide or modulating agent to a target tissue, thereby increasing the local concentration. Targeting agents include antibodies or fragments thereof, receptors, ligands and other molecules that bind to cells of, or in the vicinity of, the target tissue. Known targeting agents include serum hormones, antibodies against cell surface antigens, lectins, adhesion molecules, tumor cell surface binding ligands, steroids, cholesterol, lymphokines, fibrinolytic enzymes and those drugs and proteins that bind to a desired target site. An antibody targeting agent may be an intact (whole) molecule, a fragment thereof, or a functional equivalent thereof. Linkage is generally covalent and may be achieved by, for example, direct condensation or other reactions, or by way of bi- or multi-functional linkers. Within other embodiments, it may also be possible to target a polynucleotide encoding a polypeptide or modulating agent to a target tissue, thereby increasing the local concentration. Such targeting may be achieved using well known techniques, including retroviral and adenoviral infection. To treat a patient afflicted with certain conditions (*e.g.*, neurodegenerative conditions), it may be beneficial to deliver an ADAMTS polypeptide, polynucleotide or modulating agent to the intracellular space. Such targeting may be achieved using well known

techniques, such as through the use of polyethylene glycol or liposomes, as described in Turrens, *Xenobiotica* 21:1033-1040, 1991.

For certain embodiments, it may be beneficial to also, or alternatively, link a drug to a polypeptide or modulating agent. As used herein, the term "drug" refers to any bioactive agent intended for administration to a mammal to prevent or treat a disease or other undesirable condition.

Within certain aspects of the present invention, one or more polypeptides, polynucleotides or modulating agents as described herein may be present within a pharmaceutical composition or vaccine. A pharmaceutical composition further comprises one or more pharmaceutically or physiologically acceptable carriers, diluents or excipients. Vaccines may comprise one or more such compounds and a non-specific immune response enhancer. A non-specific immune response enhancer may be any substance that enhances an immune response to an exogenous antigen. Examples of non-specific immune response enhancers include adjuvants and liposomes.

To prepare a pharmaceutical composition, an effective amount of one or more polypeptides, polynucleotides and/or modulating agents is mixed with a suitable pharmaceutical carrier. Solutions or suspensions used for parenteral, intradermal, subcutaneous or topical application can include, for example, a sterile diluent (such as water), saline solution, fixed oil, polyethylene glycol, glycerin, propylene glycol or other synthetic solvent; antimicrobial agents (such as benzyl alcohol and methyl parabens); antioxidants (such as ascorbic acid and sodium bisulfite) and chelating agents (such as ethylenediaminetetraacetic acid (EDTA)); buffers (such as acetates, citrates and phosphates). If administered intravenously, suitable carriers include physiological saline or phosphate buffered saline (PBS), and solutions containing thickening and solubilizing agents, such as glucose, polyethylene glycol, polypropylene glycol and mixtures thereof. In addition, other pharmaceutically active ingredients and/or suitable excipients such as salts, buffers and stabilizers may, but need not, be present within the composition.

A pharmaceutical composition is generally formulated and administered to exert a therapeutically useful effect while minimizing undesirable side effects. The

number and degree of acceptable side effects depend upon the condition for which the composition is administered. For example, certain toxic and undesirable side effects that are tolerated when treating life-threatening illnesses, such as tumors, would not be tolerated when treating disorders of lesser consequence. The concentration of active  
5 component in the composition will depend on absorption, inactivation and excretion rates thereof, the dosage schedule and the amount administered, as well as other factors that may be readily determined by those of skill in the art.

A polypeptide, polynucleotide or modulating agent may be prepared with carriers that protect it against rapid elimination from the body, such as time release  
10 formulations or coatings. Such carriers include controlled release formulations, such as, but not limited to, implants and microencapsulated delivery systems, and biodegradable, biocompatible polymers, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, polyorthoesters, polylactic acid and others known to those of ordinary skill in the art. Such formulations may generally be prepared using well known technology and  
15 administered by, for example, oral, rectal or subcutaneous implantation, or by implantation at the desired target site. Sustained-release formulations may contain a polynucleotide, polypeptide or modulating agent dispersed in a carrier matrix and/or contained within a reservoir surrounded by a rate controlling membrane. Preferably the formulation provides a relatively constant level of modulating agent release. The  
20 amount of active component contained within a sustained release formulation depends upon the site of implantation, the rate and expected duration of release and the nature of the condition to be treated or prevented.

Pharmaceutical compositions of the present invention may be administered in a manner appropriate to the disease to be treated (or prevented).  
25 Administration may be effected by incubation of cells *ex vivo* or *in vivo*, such as by topical treatment, delivery by specific carrier or by vascular supply. Appropriate dosages and a suitable duration and frequency of administration will be determined by such factors as the condition of the patient, the type and severity of the patient's disease and the method of administration. In general, an appropriate dosage and treatment  
30 regimen provides the polypeptide, polynucleotide and/or modulating agent(s) in an

amount sufficient to provide therapeutic and/or prophylactic benefit (*i.e.*, an amount that ameliorates the symptoms or treats or delays or prevents progression of the condition). The precise dosage and duration of treatment is a function of the disease being treated and may be determined empirically using known testing protocols or by testing the compositions in model systems known in the art and extrapolating therefrom. Dosages may also vary with the severity of the condition to be alleviated. The composition may be administered one time, or may be divided into a number of smaller doses to be administered at intervals of time. In general, the use of the minimum dosage that is sufficient to provide effective therapy is preferred. Patients may generally be monitored for therapeutic effectiveness using assays suitable for the condition being treated or prevented, which will be familiar to those of ordinary skill in the art, and for any particular subject, specific dosage regimens may be adjusted over time according to the individual need.

For pharmaceutical compositions comprising polynucleotides, the polynucleotide may be present within any of a variety of delivery systems known to those of ordinary skill in the art, including nucleic acid, bacterial and viral expression systems, and colloidal dispersion systems such as liposomes. Appropriate nucleic acid expression systems contain the necessary DNA sequences for expression in the patient (such as a suitable promoter and terminating signal, as described above). The DNA may also be "naked," as described, for example, in Ulmer et al., *Science* 259:1745-1749, 1993.

Various viral vectors that can be used to introduce a nucleic acid sequence into the targeted patient's cells include, but are not limited to, vaccinia or other pox virus, herpes virus, retrovirus, or adenovirus. Techniques for incorporating DNA into such vectors are well known to those of ordinary skill in the art. Preferably, the retroviral vector is a derivative of a murine or avian retrovirus including, but not limited to, Moloney murine leukemia virus (MoMuLV), Harvey murine sarcoma virus (HaMuSV), murine mammary tumor virus (MuMTV), and Rous Sarcoma Virus (RSV). A retroviral vector may additionally transfer or incorporate a gene for a selectable marker (to aid in the identification or selection of transduced cells) and/or a gene that

encodes the ligand for a receptor on a specific target cell (to render the vector target specific).

Viral vectors are typically non-pathogenic (defective), replication competent viruses, which require assistance in order to produce infectious vector particles. This assistance can be provided, for example, by using helper cell lines that contain plasmids that encode all of the structural genes of the retrovirus under the control of regulatory sequences within the LTR, but that are missing a nucleotide sequence which enables the packaging mechanism to recognize an RNA transcript for encapsulation. Such helper cell lines include (but are not limited to) Ψ2, PA317 and PA12. A retroviral vector introduced into such cells can be packaged and vector virion produced. The vector virions produced by this method can then be used to infect a tissue cell line, such as NIH 3T3 cells, to produce large quantities of chimeric retroviral virions.

Another targeted delivery system for polynucleotides is a colloidal dispersion system. Colloidal dispersion systems include macromolecule complexes, nanocapsules, microspheres, beads, and lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes. A preferred colloidal system for use as a delivery vehicle *in vitro* and *in vivo* is a liposome (*i.e.*, an artificial membrane vesicle). RNA, DNA and intact virions can be encapsulated within the aqueous interior and delivered to cells in a biologically active form. The preparation and use of liposomes is well known to those of ordinary skill in the art.

#### THERAPEUTIC APPLICATIONS

As noted above, ADAMTS polynucleotides, polypeptides and modulating agents may generally be used for the therapy of diseases characterized by neuroinflammation or neurodegeneration. In general, ADAMTS metalloproteinases are believed to function in cleaving proteins from cell surfaces (which may be surfaces of cells that synthesize the metalloproteinase or other cells). Pharmaceutical compositions as provided herein may be administered to a patient, alone or in combination with other therapies, to treat or prevent neurodegenerative diseases such as Alzheimer's disease,

Parkinson's disease or stroke. Pharmaceutical compositions provided herein may also be beneficial for therapy of conditions related to cell proliferation, cell migration, inflammation or angiogenesis. Such conditions include cancer, arthritis and autoimmune diseases.

5                   Modulation of an ADAMTS function, either *in vitro* or *in vivo*, may generally be achieved by administering a modulating agent that inhibits ADAMTS transcription, translation or activity. In some instances, however, the ADAMTS activity may be lower than is desired. In such cases, polynucleotides, polypeptides and/or modulating agents that enhance ADAMTS activity may be administered. The activity  
10 of an endogenous ADAMTS protein within a cell may be increased by, for example, inducing expression of the ADAMTS gene and/or administering a modulating agent that enhances ADAMTS activity. Each of these methods may be performed using mammalian cells in culture or within a mammal, such as a human.

                  Certain ADAMTS polypeptides may be used to cleave the proteoglycan  
15 brevican. Brevican is a brain specific proteoglycan. The secreted form of brevican is upregulated in response to CNS injury and has been implicated in reactive gliosis, and a cleaved form may be important for tumor invasion (*see* Zhang et al., *J. Neuroscience* 18:2370-76, 1998). Thus, brevican cleavage appears to be important in brain injury and gliomas. Modulating agents that inhibit the ability of such ADAMTS polypeptides to  
20 cleave brevican may be used to treat brain injuries, brain tumors and other invasive tumors.

                  Routes and frequency of administration, as well as dosage, will vary from individual to individual, and may be readily established using standard techniques. In general, the pharmaceutical compositions and vaccines may be administered by  
25 injection (e.g., intracutaneous, intramuscular, intravenous or subcutaneous), intranasally (e.g., by aspiration) or orally. A suitable dose is an amount of a compound that, when administered as described above, is capable of causing modulation of an ADAMTS activity that leads to an improved clinical outcome (e.g., more frequent remissions, complete or partial or longer disease-free survival) in vaccinated patients as compared  
30 to non-vaccinated patients. In general, an appropriate dosage and treatment regimen



provides the active compound(s) in an amount sufficient to provide therapeutic and/or prophylactic benefit. Such a response can be monitored by establishing an improved clinical outcome (*e.g.*, more frequent remissions, complete or partial, or longer disease-free survival) in treated patients as compared to non-treated patients. In general, suitable dose sizes will vary with the size of the patient, but will typically range from about 0.1 mL to about 5 mL.

#### DIAGNOSTIC APPLICATIONS

In a related aspect of the present invention, kits for detecting ADAMTS proteins are provided. Such kits may be designed for detecting the level of ADAMTS protein or nucleic acid encoding an ADAMTS protein within a sample. In general, the kits of the present invention comprise one or more containers enclosing elements, such as reagents or buffers, to be used in the assay. A kit for detecting the level of ADAMTS protein or nucleic acid typically contains a reagent that binds to the ADAMTS protein, DNA or RNA. To detect nucleic acid, the reagent may be a nucleic acid probe or a PCR primer. To detect protein, the reagent is typically an antibody. A kit may also contain a reporter group suitable for direct or indirect detection of the reagent as described above.

The following Examples are offered by way of illustration and not by way of limitation.

## EXAMPLES

Example 15                    Preparation of Novel ADAMTS Family Members

This Example illustrates the cloning of cDNA molecules encoding members of the ADAMTS family of metalloproteinases based on induction of expression in rat glial cells by aggregated beta amyloid.

Subtractive hybridization was performed as described (Kelner and Maki.  
10    *Methods in Molecular Medicine*, vol 22: *Neurodegeneration Methods and Protocols*,  
Eds J. Harry and H.A. Tilson, Human Press Inc., Totowa, NJ). Briefly, rat glial cells  
were cultured and treated with aggregated beta amyloid. After 24 hours, RNA was  
prepared from these cells and from control cells that were not treated with beta amyloid.  
Genes expressed in the activated cells but not the control cells were sequenced. This  
15    screen identified rat ADAMTS-3 (cDNA and encoded protein sequences shown in  
Figure 26 (SEQ ID NO:25) and Figure 27 (SEQ ID NO:26), respectively). The rat  
cDNA was used to screen a human cDNA library and resulted in the isolation of human  
ADAMTS-3. ADAMTS-3 is 2,866 nucleotides in length (Figures 9A and 9B; SEQ ID  
NO:9) and codes for a putative protein that is 955 amino acids in length (Figure 10;  
20    SEQ ID NO:10). ADAMTS-3 contains a metalloproteinase domain, a disintegrin  
domain, thrombospondin motifs and an ECM domain.

Example 225                    Preparation of Novel ADAMTS Family Members using Degenerate PCR

This Example illustrates the use of degenerate PCR to clone partial cDNA molecules encoding members of the ADAMTS family of metalloproteinases.

PCR was performed using rat microglia cDNA and degenerate oligonucleotides derived from an analysis of the sequence from ADAMTS-1 and  
30    ADAMTS-3. Degenerate primers were designed based on common sequences between

these two genes. The original degenerate primers were designed based on a small region of these two genes that was cloned. One primer had the sequence 5'-TTYMGNGARGARCARTGY-3' (SEQ ID NO:33), while the other primer had the sequence 5'-RCANAYNCCRCAYTTRTC-3' (SEQ ID NO:34). The PCR conditions were annealing at 47°C for 1 minute, 72°C extension for 2 minutes and 94°C denaturation for 30 seconds.

Following PCR samples were fractionated by gel electrophoresis and fragments of the expected size were cloned into the vector pCRScript and sequenced. One amplified cDNA molecule was designated rat ADAMTS-2 (Figure 24; SEQ ID NO:23), and the encoded protein has the predicted sequence shown in Figure 25 (SEQ ID NO:24). This cDNA was used to screen a human cDNA library, from which human ADAMTS-2 was identified. Human ADAMTS-2 has the sequence shown in Figure 1 (SEQ ID NO:1), and appears to encode the protein recited in Figure 2 (SEQ ID NO:2).

Rat ADAMTS-4 was isolated using the PCR approach and is a polynucleotide having the sequence shown in Figures 3A and 3B (SEQ ID NO:3), which appears to encode the protein recited in Figure 4 (SEQ ID NO:4). For rat ADAMTS-4 the metalloproteinase domain begins at amino acid 260(R), the disintegrin domain begins at residue 487(Q), a thrombospondin motif begins at residue 570(W) and an ECM domain begins at residue 621(C). The rat ADAMTS-4 sequence was used to screen a human cDNA library and human ADAMTS-4 was isolated. Human ADAMTS-4 is 1455 nucleotides in length (Figure 15; SEQ ID NO:15) and codes for a putative protein that is 485 amino acids in length (Figure 16; SEQ ID NO:16). The disintegrin domain in human ADAMTS-4 begins at amino acid 39(E), the start of the first thrombospondin repeat is at amino acid 124(W) and the start of another thrombospondin repeat is at amino acid 479(C). Bovine ADAMTS-4 cDNA has the sequence shown in Figure 18 (SEQ ID NO:17), encoding the predicted amino acid sequence shown in Figure 19 (SEQ ID NO:18).

Rat ADAMTS-5 is a cDNA molecule with the sequence shown in Figure 13 (SEQ ID NO:13), encoding the amino acid sequence shown in Figure 14 (SEQ ID

NO:14). The human ADAMTS cDNA and protein sequences are shown in Figure 22 (SEQ ID NO:21) and Figure 23 (SEQ ID NO:22), respectively.

ADAMTS-4 was further shown to cleave the brain-specific proteoglycan brevican. Five hundred micrograms of purified brevican was cleaved with 500 micrograms of human ADAMTS-4 and incubated overnight at 37°C. The cleavage reaction was vacuum dried and resuspended in SDS sample loading dye for running on a 4-20% SDS polyacrylamide gel. Equal amounts of cleaved and uncleaved brevican were added to the gel. After electrophoresis the gel was stained with Coomassie Blue to visualize the protein bands. The results, presented in Figure 30, show that brevican is cleaved upon incubation with ADAMTS-4.

### Example 3

#### Identification of ADAMTS Family Members using Database Searches

This Example illustrates the use of database searches to identify cDNA molecules encoding members of the ADAMTS family of metalloproteinases.

To identify additional members of the ADAMTS family, the GenBank database was searched for sequences similar to ADAMTS-1 and ADAMTS-3. This search retrieved KIAA0605 (Figures 5A and 5B; SEQ ID NO:5), which appears to encode a protein of 951 amino acids (Figure 6; SEQ ID NO:6). The coding sequence contains thrombospondin motifs, but no metalloproteinase or disintegrin domains have been identified. A thrombospondin motif begins with amino acid 50(W). Six additional thrombospondin motifs were found beginning with amino acid 568(K). The domain that binds to the extracellular matrix begins with amino acid 105(C).

Also retrieved was KIAA0366 (Figures 7A and 7B; SEQ ID NO:7), which appears to encode a protein of 951 amino acids (Figure 8; SEQ ID NO:8), including metalloproteinase and disintegrin domains, as well as thrombospondin motifs. For KIAA0366, the metalloproteinase domain begins with amino acid 241(T), the disintegrin domain begins with amino acid 460(D), a thrombospondin domain is present beginning at position 544(W) and another thrombospondin repeat occurs at position

842(W). The ECM domain begins at amino acid 597(C) and contains the semiconserved sequence FREEQC (SEQ ID NO:32). KIAA0366 does not appear to have a transmembrane domain, and therefore is likely to encode a secreted protein.

An additional sequence identified in this search was KIAA0688 (Figures 11A and 11B; SEQ ID NO:11), which appears to encode the protein shown in Figure 12 and SEQ ID NO:12. This gene codes for a protein with a metalloproteinase domain beginning at amino acid 245(R), a disintegrin domain beginning at amino acid 465(E), a thrombospondin motif at position 550(W), an ECM domain at position 601(C) and two additional thrombospondin motifs at position 905(W). A bovine KIAA0688 cDNA sequence is shown in Figure 20 (SEQ ID NO:19), and the predicted amino acid sequence of the encoded protein is shown in Figure 21 (SEQ ID NO:20).

Figures 17A-17G present an alignment of the ADAMTS protein sequences described herein, along with ADAMTS-1.

15

#### Example 4

##### Identification and Characterization of ADAMTS-9

This Example illustrates the cloning and characterization of the ADAMTS/metallospodin family member designated herein as ADAMTS-9.

A small fragment of the rat ADAMTS-9 gene was initially cloned from a beta amyloid-treated (35 µg/ml aggregated Aβ 1-42) rat astrocyte cDNA library. DNA sequence analysis was performed using a PCR procedure employing fluorescent dideoxynucleotides and a model ABI-377 automated sequencer (PE Biosystem). BLAST sequence analysis revealed low homology at the protein level to the spacer region of the murine ADAMTS-1 gene.

This clone was labeled with [ $\alpha$ -<sup>32</sup>P]dCTP using the Prime It II kit (Stratagene) and used to screen a human spinal cord phage library (Clontech) according to the manufacturer's instructions. Positive plaques were purified and lambda DNA prepared (Qiagen). Several overlapping clones were sequenced that had homology to the original rat clone. In order to determine the 5' and 3' ends of the gene RACE (rapid

30

amplification of cDNA ends) analysis was performed using Marathon Ready placenta and fetal cDNA libraries (Clontech) with SMART primers (Clontech). Overlapping sequence was used to confirm the full length clone. The full length protein sequence of human ADAMTS-9 is shown in Figure 29. The 5' end of the clone contains a methionine codon within a good Kozak consensus for translation initiation. A signal peptide sequence is located just downstream of this methionine in the translated ORF, and the size of the pro-domain is similar to that of other ADAM-TS family members. Therefore, this appears to be the starting methionine of ADAMTS-9.

The overall protein sequence of ADAMTS-9 is similar to that of the other ADAM-TS proteins. All of these family members have a pro-domain, metalloprotease domain, disintegrin-like domain, thrombospondin domain, spacer region, and a variable number of a thrombospondin-like submotifs at the carboxyl-terminal end of the protein (Figure 32A). Like other ADAM-TS family members, ADAMTS 9 contains an amino-terminal signal peptide sequence and lacks a transmembrane domain.

Among the 23 ADAM family members, 10 are predicted to be active proteases based on the sequence of their Zn binding catalytic sites (Black and White, *Curr. Opin. Cell. Biol* 10:654-659, 1998). The consensus catalytic sequence site based on ADAM and snake venom metalloproteases is HEXGHXXGXXHD (SEQ ID NO:51). The ADAM-TS family of proteins has homology to this consensus sequence except at the second conserved glycine. ADAMTS 9 has an asparagine at this conserved glycine site in the helix. Two other ADAM-TS proteins, ADAMTS-1 and ADAMTS-4, also have an asparagine in this position instead of glycine (Figure 32B). This suggests that ADAMTS-9, like ADAMTS-1 and ADAMTS-4, may have an active metalloprotease domain.

It has been proposed that an invariant cysteine residue in the pro-domain of MMP and ADAM proteins coordinates the catalytic Zn ion in the metalloprotease domain, thus maintaining the protease in an inactive state (Loechel et al., *J. Biol Chem.* 274:13427-33, 1999). Once the pro-domain is cleaved this interaction is interrupted and the protease is activated by a "cysteine switch" mechanism. A proposed cysteine switch

residue in ADAMTS-9 is marked in Figure 29 by a star. Proteolytic processing of the pro-domain of ADAM and ADAM-TS proteins is believed to occur by furin endopeptidases in the Golgi. ADAMTS-9 contains two potential furin cleavage sites (consensus RX(K/R)R; SEQ ID NO:35) at the end of the pro-domain (see Figure 29).

5 Based on the sequence of mature murine *ADAMTS-1*, the second furin cleavage site is most likely used in ADAMTS-9 (resulting amino-terminus FLSYPR).

Following the metalloprotease domain, ADAMTS-9 contains a cysteine-rich region that has homology to the disintegrin domain in snake venom metalloprotease and ADAMs. Next, all of the ADAM-TS family members contain an  
10 internal TSP1 motif that has the two conserved heparin binding segments: W(S/G)XWSXW (SEQ ID NO:36) and CSVTCG (SEQ ID NO:37). Separating the internal TSP1 motif and the carboxy terminal TSP1-like submotifs is a variable length spacer region. As seen in Figure 32A, most ADAM-TS family members have between one and three TSP1-like submotifs at the end of the protein. However at the extremes  
15 are ADAMTS 3 which has no TSP1-like motifs and *C. elegans* GON-1 which has 17 of these motifs. ADAMTS-9 contains one internal TSP1 motif and three TSP-1 like submotifs at the carboxyl end (Figure 30A). A possible role for ADAMTS 9 in the adult is suppression of angiogenesis through the carboxy-terminal TSP1 motifs.

Overall, the predicted mature forms of the ADAM-TS proteins show 20-  
20 40% similarity to each other. Interestingly, by BLAST analysis ADAMTS-9 shows as much homology to *C. elegans* GON-1 as to other human ADAM-TS, suggesting that ADAMTS 9 may be the human homologue of GON-1. The dendrogram in Figure 30C (prepared with the MegAlign program (DNASar)) shows the relationship between the known human ADAM-TS members, ADAMTS 9, and GON-1.

25 The expression pattern of ADAMTS 9 was examined in a variety of human adult and fetal tissues using RT-PCR. For tissue distribution analysis, human multiple tissue cDNA panels I and II were purchased from Clontech. RT-PCR was performed using a touchdown procedure where the annealing temperature was dropped from 63°C to 57°C over 10 cycles then kept at 57°C for 20 cycles. The sense primer  
30 was CAGGGGAAACAGACGATGACAACT (SEQ ID NO:38) and the antisense

primer was TGCGGTAACCCAAGCCACACT (SEQ ID NO:39). Expected product size was 510 bp. Control primers to glyceraldehyde-3-phosphate dehydrogenase (G3PDH) were supplied by Clontech--expected size is about 1 kb.

As seen with other ADAM-TS genes, Northern blot analysis showed  
5 very low levels of expression. Therefore a more sensitive RT-PCR procedure was used. The cDNA panels used were normalized to the mRNA expression levels of several different housekeeping genes to ensure accurate assessment of tissue specificity. ADAMTS-9 was found in ovary, pancreas, heart, kidney, lung, placenta, and strikingly in all fetal tissues examined (Figure 31), suggesting a possible role in development. In  
10 addition, using hybridization to cDNA libraries we have identified ADAMTS-9 in adult spinal cord and brain. However, ADAMTS-9 was not detected in colon, leukocyte, prostate, small intestine, testis, liver, skeletal muscle, spleen or thymus (Figure 31). Expression of the G3PDH housekeeping gene in all cDNAs tested is shown as a control  
15 for template integrity and the RT-PCR procedure. One notable difference in the expression pattern of ADAMTS-9 compared to other ADAMTS genes is the presence of ADAMTS-9 in the adult kidney. This is of interest since the chromosomal locus containing ADAMTS-9 is often deleted in renal tumors.

A genomic clone of ADAMTS 9 was obtained by screening a human P1 library and used for FISH analysis (Genome Systems). Briefly, the human ADAMTS-9  
20 genomic clone was labeled with digoxigenin dUTP by nick translation. Labeled probe was combined with sheared human DNA and hybridized to normal metaphase chromosomes derived from PHA stimulated peripheral blood lymphocytes in a solution containing 50% formamide, 10% dextran sulfate and 2X SSC. Specific hybridization signals were detected by incubating the hybridized slides in fluoresceinated  
25 antidigoxigenin antibodies followed by counterstaining with DAPI for one-color experiments. Probe detection for two-color experiments was accomplished by incubating the slides in fluoresceinated antidigoxigenin antibodies and Texas red avidin followed by counterstaining with DAPI. A total of 80 metaphase cells were analyzed with 70 exhibiting specific labeling. Initial FISH experiments resulted in specific  
30 labeling of the short arm of chromosome 3. Measurement of 10 specifically labeled



chromosome 3's demonstrated that ADAMTS-9 is located at a position which is 30% the distance from the centromere to the telomere of chromosome arm 3p, an area which corresponds to 3p14.3-21.1 (Figures 32A and 32B). Since deletions and other rearrangements of this locus are frequent and early events in the pathogenesis of a number of human cancers (including renal cell carcinoma, breast cancers, uterine cervical carcinoma and vulvar carcinomas, this region may contain one or more tumor suppressor genes.

The chromosomal localization of the human ADAMTS 9 locus was independently confirmed by PCR analysis of the Stanford G3 radiation hybrid mapping panel. The G3 hybrid mapping panel (Stewart et al., *Genomic Res.* 7:422-433, 1997) containing 83 radiation hybrid DNA, as well as human and hamster control DNAs was obtained from Research genetics Inc. (Huntsville, Alabama). The human chromosome content of each somatic cell hybrid was established by the Stanford Human Genome Center using more than 10,000 STSs derived from random genetic markers and expressed tagged sequences (<http://www-shgc.stanford.edu/Mapping/rh/>). PCR reactions were carried out in a 10 µl reaction volume containing 25 ng DNA template, 25 µM deoxynucleotide triphosphates, 20 pmol of each oligonucleotide primer, 0.5 U of Taq polymerase (Boehringer Mannheim), 2.5 mM MgCl<sub>2</sub>, 50 mM KCl and 10 mM Tris-HCl (pH 8.3). The sense primer is GTGCGCTGGGTCCCTAAATAC (SEQ ID NO:40) which is in the coding sequence and the antisense primer is AAAATCACAGGTTGGCAGCGG (SEQ ID NO:41) which is in an intronic sequence. Thirty cycles of PCR were performed. Ten cycles consisted of denaturing at 94°C for 15 seconds, annealing at 62°C for 30 seconds, going down 0.5°C each cycle and extension at 72°C for 30 seconds. Twenty more cycles were performed using the same denaturing and extension conditions and keeping the annealing at 57°C for 30 seconds. PCR was proceeded by a 2 min incubation at 94°C and followed by a 72°C final soak for 10 minutes. Amplified products were electrophoresed through a 2% agarose gel and visualized by ethidium bromide staining. The resulting PCR product was a 302 bp human specific fragment. The presence or absence of the ADAMTS 9 product was scored for each of the somatic cell hybrids. The results were submitted to the Stanford

Radiation Hybrid Server via the internet (<http://www-shgc.stanford.edu>) and the completed data were returned to us. ADAMTS 9 was linked to the ordered markers SHGC-33668 with a LOD score of 11.47 and SHGC-20118 (D3S3571) with a LOD score of 11.06. The results confirm localization of ADAMTS 9 to the short arm of chromosome 3 and place ADAMTS-9 within the context of established maps. Furthermore SHGC-20118 (D3S3571) has been mapped to 3p14.2, placing ADAMTS-9 closer to the 14.2-14.3 region of chromosome 3. This location is interesting in that it contains a well characterized breakpoint for translocations common in hereditary renal cell carcinomas.

From the foregoing, it will be appreciated that, although specific embodiments of the invention have been described herein for the purpose of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the present invention is not limited except as by the appended claims.

## CLAIMS

1. An isolated polynucleotide that encodes an ADAMTS polypeptide, wherein the polypeptide comprises:

(a) at least 50 consecutive amino acid residues of an ADAMTS protein that comprises a sequence recited in any one of SEQ ID NOs:2, 4, 10, 14, 16, 18, 22, 24, 26 or 27; or

(b) a variant of any of the foregoing amino acid sequences that differs in one or more substitutions, deletions, additions and/or insertions, wherein substitutions, if any, are present at no more than 10% of the consecutive residues of the ADAMTS protein.

2. A polynucleotide according to claim 1, wherein the polynucleotide comprises a sequence recited in any one of SEQ ID NOs:1, 3, 9, 13, 15, 17, 21, 23 or 25.

3. A polynucleotide according to claim 1, wherein substitutions, if any, are present at no more than 5% of the consecutive residues of the ADAMTS protein.

4. A polynucleotide according to claim 1, wherein the polypeptide has an ADAMTS activity that is not substantially diminished relative to the ADAMTS protein.

5. A recombinant expression vector comprising a polynucleotide according to claim 1.

6. A host cell transformed or transfected with an expression vector according to claim 5.

7. An isolated antisense polynucleotide complementary to at least 20 consecutive nucleotides present within a polynucleotide according to claim 1.

8. A method for preparing an ADAMTS polypeptide, the method comprising:

(a) culturing a host cell transformed or transfected with an expression vector comprising a polynucleotide that encodes an ADAMTS polypeptide comprising:

(i) at least 50 consecutive amino acid residues of an ADAMTS protein that comprises a sequence recited in any one of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 or 27; or

(ii) a variant of any of the foregoing amino acid sequences that differs in one or more substitutions, deletions, additions and/or insertions, wherein substitutions, if any, are present at no more than 10% of the consecutive residues of the ADAMTS protein;

wherein the step of culturing is performed under conditions promoting expression of the polynucleotide sequence; and

(b) recovering an ADAMTS polypeptide.

9. A method for preparing an ADAMTS polypeptide, the method comprising:

(a) culturing a host cell according to claim 6 under conditions promoting expression of the polynucleotide; and

(b) recovering an ADAMTS polypeptide.

10. An isolated ADAMTS polypeptide comprising:

(a) at least 50 consecutive amino acid residues of an ADAMTS protein that comprises a sequence recited in any one of SEQ ID NOs:2, 4, 10, 14, 16, 18, 22, 24, 26 or 27; or

(b) a variant of any of the foregoing amino acid sequences that differs in one or more substitutions, deletions, additions and/or insertions, wherein substitutions, if any, are present at no more than 10% of the consecutive residues of the ADAMTS protein.

11. An ADAMTS polypeptide according to claim 10, wherein the polypeptide has an ADAMTS activity that is not substantially diminished relative to the ADAMTS protein.

12. A polypeptide comprising an amino acid sequence recited in any one of SEQ ID NOs:2, 4, 10, 14, 16, 18, 22, 24, 26 or 27.

13. An isolated ADAMTS polypeptide comprising:

(a) at least 50 consecutive amino acid residues of an ADAMTS protein that comprises a sequence recited in any one of SEQ ID NOs:6, 8, 12, or 20

(b) a variant of any of the foregoing amino acid sequences that differs in one or more substitutions, deletions, additions and/or insertions, wherein substitutions, if any, are present at no more than 10% of the consecutive residues of the ADAMTS protein.

14. An ADAMTS polypeptide according to claim 13, wherein the polypeptide has an ADAMTS activity that is not substantially diminished relative to the ADAMTS protein.

15. An ADAMTS polypeptide according to claim 13, wherein the polypeptide comprises at least 40 consecutive amino acid residues of an ADAMTS protein that comprises a sequence recited in any one of SEQ ID NOs:6, 8, 12, or 20.

16. A polypeptide comprising an amino acid sequence recited in any one of SEQ ID NOs:6, 8, 12, or 20.

17. A pharmaceutical composition comprising:

(a) an ADAMTS polypeptide comprising:

(i) at least 50 consecutive amino acid residues of an ADAMTS protein that comprises a sequence recited in any one of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 or 27; or

(ii) a variant of any of the foregoing amino acid sequences that differs in one or more substitutions, deletions, additions and/or insertions, wherein substitutions, if any, are present at no more than 10% of the consecutive residues of the ADAMTS protein; and

(b) a physiologically acceptable carrier.

18. A vaccine comprising:

(a) an ADAMTS polypeptide comprising:

(i) at least 50 consecutive amino acid residues of an ADAMTS protein that comprises a sequence recited in any one of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 or 27; or

(ii) a variant of any of the foregoing amino acid sequences that differs in one or more substitutions, deletions, additions and/or insertions, wherein substitutions, if any, are present at no more than 10% of the consecutive residues of the ADAMTS protein; and

(b) a non-specific immune response enhancer.

19. An isolated antibody, or antigen-binding fragment thereof, that specifically binds to an ADAMTS polypeptide that comprises a sequence recited in any one of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 or 27.

20. A method for screening for an agent that modulates ADAMTS protein expression in a cell, comprising:

(a) contacting a candidate modulator with a cell expressing an ADAMTS polypeptide, wherein the polypeptide comprises:

(i) at least 50 consecutive amino acid residues of an ADAMTS protein that comprises a sequence recited in any one of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 or 27; or

(ii) a variant of any of the foregoing amino acid sequences that differs in one or more substitutions, deletions, additions and/or insertions, wherein

substitutions, if any, are present at no more than 10% of the consecutive residues of the ADAMTS protein; and

(b) subsequently evaluating the effect of the candidate modulator on expression of an ADAMTS mRNA or polypeptide, and therefrom identifying an agent that modulates ADAMTS protein expression in the cell.

21. A method for screening for an agent that modulates an ADAMTS protein activity, comprising:

(a) contacting a candidate modulator with an ADAMTS polypeptide, comprising:

(i) at least 50 consecutive amino acid residues of an ADAMTS protein that comprises a sequence recited in any one of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 or 27; or

(ii) a variant of any of the foregoing amino acid sequences that differs in one or more substitutions, deletions, additions and/or insertions, wherein substitutions, if any, are present at no more than 10% of the consecutive residues of the ADAMTS protein;

wherein the polypeptide has an ADAMTS activity that is not substantially diminished relative to the ADAMTS protein;

and wherein the step of contacting is carried out under conditions and for a time sufficient to allow the candidate modulator to interact with the polypeptide; and

(b) subsequently evaluating the effect of the candidate modulator on an ADAMTS activity of the polypeptide, and therefrom identifying an agent that modulates an activity of an ADAMTS protein.

22. An agent that decreases expression or activity of an ADAMTS protein that comprises a sequence recited in any one of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 or 27, for use in the manufacture of a medicament for inhibiting neuroinflammation in a patient.

23. An agent according to claim 22, wherein ADAMTS activity is decreased by inhibiting expression of an endogenous ADAMTS gene.

24. An agent according to claim 22, wherein ADAMTS activity is decreased by administering a modulating agent that binds to an ADAMTS protein.

25. An agent that decreases expression or activity of an ADAMTS protein that comprises a sequence recited in any one of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 or 27, for use in the manufacture of a medicament for inhibiting neurodegeneration in a patient.

26. An agent according to claim 25, wherein ADAMTS activity is decreased by inhibiting expression of an endogenous ADAMTS gene.

27. An agent according to claim 25, wherein ADAMTS activity is decreased by administering a modulating agent that binds to an ADAMTS protein.

28. A pharmaceutical composition according to claim 17, for use in the manufacture of a medicament for method for treating a patient afflicted with a condition associated with neuroinflammation and/or neurodegeneration.

29. A composition according to claim 28, wherein the condition is selected from the group consisting of Alzheimer's disease, Parkinson's disease and stroke.

30. A method for modulating ADAMTS activity in a cell, comprising contacting a cell expressing an ADAMTS polypeptide with an effective amount of an agent that modulates ADAMTS protein activity or expression, wherein the ADAMTS polypeptide comprises:



(i) at least 50 consecutive amino acid residues of an ADAMTS protein that comprises a sequence recited in any one of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 or 27; or

(ii) a variant of any of the foregoing amino acid sequences that differs in one or more substitutions, deletions, additions and/or insertions, wherein substitutions, if any, are present at no more than 10% of the consecutive residues of the ADAMTS protein;

wherein the polypeptide has an ADAMTS activity that is not substantially diminished relative to the ADAMTS protein;

and thereby modulating ADAMTS activity in the cell.

31. A pharmaceutical composition according to claim 17, for use in the manufacture of a medicament for treating a patient afflicted with a condition associated with cell proliferation, cell migration, inflammation and/or angiogenesis.

32. A composition according to claim 31, wherein the condition is selected from the group consisting of cancer, arthritis and autoimmune diseases.

33. An agent that decreases expression or activity of an ADAMTS protein that comprises a sequence recited in any one of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 or 27, for use in the manufacture of a medicament for treating a patient afflicted with an invasive tumor.

34. An agent that decreases expression or activity of an ADAMTS protein that comprises a sequence recited in any one of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 or 27, for use in the manufacture of a medicament for treating a patient afflicted with a brain tumor.

35. An agent that decreases expression or activity of an ADAMTS protein that comprises a sequence recited in any one of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 20,

22, 24, 26 or 27, for use in the manufacture of a medicament for treating a patient afflicted with a brain injury.

36. An agent according to any one of claims 33-35, wherein the ADAMTS protein comprises a sequence recited in SEQ ID NO:16.

1/39

AGGACCAAGCGGTTTGTGCTGAGGCGCGCTTCGTGGAGACGCTGCTGGTGGCCGATGCGTCCATGGCTGCCTTCTACGG  
GGCCGACCTGCAGAACCACATCCTGACGTTAATGTCTGTGGCAGCCCGAATCTACAAGCACCCAGCATCAAGAATTCCA  
TCAACCTGATGGTGGTAAAAGTCTGATCGTAGAAGATGAAAAATGGGGCCAGAGGTGTCCGACAATGGGGGCTTACA  
CTGCGTAACTTCTGCAACTGGCAGCGGCGTTTCAACCAGCCAGCGACCGGCACCCAGAGCACTACGACACGGCCATCCT  
GCTCACCAGACAGAACTTCTGTGGGCAGGAGGGGCTGTGTGACACCCTGGGTGTGGCAGACATCGGGACCATTTGTGACC  
CCAACAAAAGCTGCTCCGTGATCGAGGATGAGGGGCTCCAGGCGGCCACACCCTGGCCCATGAACTAGGGCACGTCTC  
AGCATGCCCCACGACGACTCCAAGCCCTGCACACGGCTCTTCGGGCCCATGGGCAAGCACCGTGTGACACCGCTGT  
CGTCCACCTGAACCAGACGCTGCCCTGGTCCCTGCAGCGCCATGTATCTCACAGAGCTTCTGGACGGCGGGCAGCGAG  
ACTGTCTCCTGGATGCCCCTGCTGCGGCCCTGCCCTCCCCACAGGCTCCCGGGCCGATGGCCCTGTACCAGCTGGAC  
CAGCAGTGCAGGCAGATCTTTGGGCCGGATTTCCGCCACTGCCCAACACCTCTGCTCAGGACGTCTGCGCCAGCTTTG  
GTGCCACACTGATGGGGCTGAGCCCTGTGCCACACAAGAATGGCAGCCTGCCCTGGGTGACGGCACGCCGTGCGGGC  
CTGGGCACCTCTGCTCAGAAGGCAGCTGTCTACCTGAGGAGGAAGTGAGAGGCCAAGCCCGTGGTAGATGGAGGCTGG  
GCACCGTGGGGACCCTGGGGAGAATGTTCTCGGACCTGTGGAGGAGGAGTACAGTTTTACACCGTGAGTGAAGGACCC  
CGAGCTCAGAATGGAGGAAGATACTGCCCTGGGTGCGAGAGCCAAGTACCAGTCAATGCCACACGGAGGAATGCCCCCTG  
ACGGGAAAAGCTTCAGGGAGCAGCAGTGTGAGAAGTATAATGCCTACAATTACACTGACATGGACGGGAATCTCTGCAG  
TGGGTCCCCAAGTATGCTGGGGTGTCCCCCGGGACCGCTGCAAGTTGTTCTGCCGAGCCCGGGGAGGAGCGAGTTCAA  
AGTGTTCGAGGCCAAGGTGATTGATGGCACCCTGTGTGGCCAGAAACACTGGCCATCTGTGTCCGTGGCCAGTGTGTCA  
AGGCCGGCTGTGACCATGTGGTGGACTCGTTTTGGAAGCTGGACAAATGCGGGGTGTGTGGGGGAAAGGCAACTCCTGC  
AGGAAGGGCTCCGGGTCCCTACCCCCACCAATTATGGCTACAATGACATTGTACCATCCCAGCTGGTGCCACTAATAT  
TGACGTGAAGCAGCGGAGCCACCCGGGTGTGAGAACGATGGGAACCTACCTGGCGCTGAAGACGGCTGATGGGCAGTACC  
TGCTCAACGGCAACCTGGCCATCTCTGCCATAGAGCAGGACATCTTGGTGAAGGGGACCATCCTGAAGTACAGCGGCTCC  
ATCGCCACCCTGGAGCGCTGCAGAGCTTCGGGCCCTTGCCAGAGCCTCTGACAGTGCAGCTCCTGGCAGTCCCTGGCGA  
GGTCTTCCCCCAAAGTCAAATACACCTTCTTTGTTCTAATGACGTGGACTTTAGCATGCAGAGCAGCAAAGAGAGAG  
CAACCACCAACATACCCAGCCGTGCTCCACGCACAGTGGGTGCTGGGGGACTGGTCTGAGTGTCTAGCACCTGCGGG  
GCCGGCTGGCAGAGCGAACTGTAGAGTGCAGGGACCCCTCGGGCAGGCCTCTGCCACCTGCAACAAGGCTCTGAAACC  
CGAGGATGCCAAGCCCTGCGAAAGCCAGCTGTGCCCCCTGTGATTGAGGGGGCAGGGGCCAGTCTTGTGCTCCTGGACA  
TGCGGTACTGAGGTGCAGACAAGGGTCTCCACTGTGGTACTGGGTCCCTTGGCCATATCAAGGCAGCACGGCCACCCA  
GGCCTCCATTGCCGCAACCCCTCCAGTACTGCACAAATCTAAGGGGGAAGAGGAGGGTATGGGGCGGCAGACCT  
ATCATCAACTGTCCAGTGGACTGGACCTTGCTCGGGTTCAAGTAGAGGGCATAGGTTAAAAGGTAAGTGCACCTATTG  
TACCAGACAGGACGCCCCGGAATTC

*Fig. 1*

2/39

RTKRFVSEARFVETLLVADASMAAFYGADLQNHILTLMSVAARIYKHPSTIKNSINLMVVKVLIVEDEKWGPEVSDNGGLT  
LRNFCNWQRRFNQPSDRHPEHYDTAILLTRQNFCCQEGLCDTLGVADIGTICDPNKSCSVIEDEGLQAAHTLAHELGHVL  
SMPHDDSKPCTRLFPGMGKHHVMAPLFVHLNQTLPWSPCSAMYLTELLDGGHGDCLLDAPAAALPLPTGLPGRMALYQLD  
QQCRQIFGPDFRHCNPNTSAQDVCAQLWCHTDGAEPLCHTKNGSLPWADGTPCGPGHLCSEGSCLPEEEVERPKPVVDGGW  
APWGPWGECSRTC GGGVQF SHRECKDPEPQNGGRYCLGRRAKYQSCHEECPPDGKSFREQQCEKYNAYNYTMDGNLLQ  
WVPKYAGVSPDRCKLFCRARGRSEFKVFEAKVIDGTLCGPETLAICVRGQCVKAGCDHVDSFWKLDKCGVCGGKGNCS  
RKGSGSLTPTNYGYNDIVTIPAGATNIDVKQRSHPGVQNDGNYLALKTADGQYLLNGNLATSAIEQDILVKGTILKYSGS  
IATLERLQSFRLPEPLTVQLLAVPGEVFPPKVYTFVVPNDVDFSMQSSKERATTNITQPLLHAQWVLGDWSECSSTCG  
AGWQRRTVECRDPSGQASATCNKALKPEDAKPCESQLCPL.

*Fig. 2*

3/39

CCCCCCTCGAGGTCGACGGTATCGATAAGCTTGATATCGAATTCGGGGCCCCACCCCCGCCCTGAACTTCTATAG  
CAAATAGCAAACATCCAGCTAGACTCAGTCGCGCAGCCCCCTCCGGCGGGCAGCGCACTATGCGGCTCGAGTGGCGTCC  
TTGCTGCTGCTACTGCTGCTGCTGTGCGCTCTGCTGGCCCTGGCCGTGACAACCTGCCGCGGCACCTGCCCAGGA  
TAAACCAGGCAGCCTCGGGCTGCTGCAGCGGCTGCCAGCCGACCAGCGGCAGTGGGAGGAAACACAGGAGCGGGGCC  
ATCTGCAACCTTGGCCAGGCAGCGCAGGAGCAGCGGGCTGGTGCAGAATATAGACCAACTCTACTCTGGCGGTGGCAAA  
GTGGGTACCTTGTCTACGCGGGCGGCGGAGGTTCTGCTGGACCTGGAGAGGGATGACACAGTGGGTGCTGCTGGTGG  
CATCGTTACTGCAGGAGGGCTGAGCGCATCCTCTGGCCACAGGGGTCACTGCTTCTACAGAGGCACTGTGGACGGCAGCC  
CTCGATCCCTAGCTGTCTTTGACCTCTGTGGGGTCTCGATGGCTTCTTCGCACTCAAGCATGCGCGCTACACTCTGAGG  
CCGCTCTTGGTGGGTCTGGGAGAGTCCGAACGAGTTTACGGGGATGGGTCTTCACGCATCCTGCATGTCTACACCCG  
CGAGGGCTTCAGCTTCGAGGCCCTGCCGCCACGCACCAAGTTGCGAGACTCCAGCGTCCCGTCTGGGGCCAAGAGAGCC  
CCTCGGTGCACAGTAGTTCTAGGCGACGCACAGAAGTGGCAGCGAGCTGTGGACCATTCAGCTTCTCGCCAGCTGGG  
AACGCGGGACCTCAGACCTGGTGGAGGCGGAGGCGCGTTCATCTCCAGGGCCGCCAGGTGGAGCTCCTCTTGGTGGC  
TGACTCTTCATGGCCAAGATGTATGGGCGGGGCTGCAGCATTACCTGCTGACCCTGGCCTCTATTGCCAACCGGCTGT  
ACAGTCATGCAAGCATCGAGAACCACATCCGCTGGCCGTAGTGAAGTGGTGGTGTGACCGACAAGAGTCTGGAGGTG  
AGCAAGAACGCGGCCACGACCTCAAGAACTTTTGCAATGGCAGCACCAACAACCAAGCTAGGTGATGACCATGAGGA  
GCACTACGATGCAGCCATCCTGTTACCCAGAGAGGATTTATGTGGGCATCATTATGTGACACCCTGGGAATGGCAGAG  
TTGGGACCATATGTTCTCGGAGCGCAGCTGCGCTGTGATTGAAGATGATGGCCTCCATGCAGCTTCTACTGTGGCTCAC  
GAAATTGGACATCTACTTGGCCTCTCTCAGCAGATTCCAAATCTGTGAAGAGAAGTTTGGTTCTACAGAAGACAAGCG  
TTTAATGTCTTCAATCCTTACCAGCATTGATGCATCCAAGCCCTGGTCCAAATGCATTTCAGCCACGATCACAGAAATTC  
TGGATGACGGTCATGGTAACTGTTTACTAGATGTACCACGAAGCAGATTCTGGGCCCCGAGGAATCCCAGGACAGACC  
TATGATGCCACCCAGCAGTGCAACTTGACATTTGGGCTGAATACTCTGTGTGCCCTGGCATGGATGTCTGTGCACGGCT  
GTGGTGTGCTGTGGTGCGCCAAGGCCAAATGGTGTGTCTGACCAAGAAGTTGCCTGCCGTGGAGGGCACTCCCTGTGGGA  
AAGGAAGAATCTGCCTGCAAGGCAATGTGTGGACAAAATAAGAAAAAATTAATCTCGACATCAAGCCATGGAAATTGG  
GGGTCTGGGGCCCTGGGGTCAGTGTTCTCGCTCTTGGGGGGAGGAGTACAGTTTGCCTACCGCCATTGCAATAACCC  
CGCACCTCGAAACAGTGGCCGCTACTGCACAGGGAAGAGGGCCATATACCGTTCTGCAGTGTACATCCCTGCCACCTA  
ACGGCAAATCTTTCGCCACGAGCAGTGTGAAGCCAAAAATGGCTATCAGTCCGATGCAAAAGGAGTCAAAACATTGTGA  
GAATGGGTTCCAAATACGAGGTGTCTGCCGGCAGAGTGTGCAAGCTTACGTGCAGAGCTAAGGGCACTGGCTATTA  
CGTGGTCTTTCTCCAAAGTTACAGATGGGACAGAAATGTAGACCCTACAGCAACTCCGTGTGTGTCCGAGGGAGGTGCG  
TGAGAACGGGTGTGACGGCATCATCGGCTCAAAGCTACAGTATGACAAGTGTGAGTGTGTGGAGGGATAACTCCAGT

*Fig. 3A*

4/39

TGTACAAAGATTATCGGAACCTTCAATAAAAAAGCAAGGGTTATACTGACGTTGTGAGGATCCCTGAAGGAGCAACCCA  
CATAAAAGTCCGACAGTTCAAAGCCMAAGACCAGACTAGATTCAGTCTTACTTAGCCCTAAAGAAGAAAAGTGGCGAGT  
ACCTTATCAACGGCAAGTACATGATCTCCACTTCAGAGACCATCATCGACATCAATGGTACCGTCATGAACACAGTGGG  
TGGAGTCACAGAGATGATTTTTTACATGGGATGGGCTATTAGCCACAAAGGAAATTCTGATTGTGCAGATCCTTGCAAC  
AGACCCAACTAAAGCATTAGACGTCGGTTACAGCTTTTTTGTTCCTCAAGAAGACCACTCAAAAAGTGAATTCCTGCAGCC  
CGGGGGATCCACTAGTTCTAGAGCGGCCG

*Fig. 3B*

MRLEWASLLLLLLLLCASCLALAADNPAAAPAQDKTRQPRAAAAAAQDQRQWEETQERGHLOPLARQRRSSGLVQNIQ  
LYSGGGKVGYL VYAGGRRFLDLERDDTVGAAGGIVTAGGLSASSGHRGHCFYRGTVDGSPRSLAVFDLCGGLDGFFAVK  
HARYTLRPLLRGSAESERVYGDGSSRILHVTREGFSEALPPRTSCETPASPSGAQESPSVHSSRRRTELAPQLLDH  
SAFSPAGNAGPQTWRRRRRSISRARQVELLLVADSSMAKMYGRGLQHYLLTLASIANRLYSHASIHRLAVVKVVL  
TDKSLVSKNAATTLKNFCKWQHQNQLGDDHEEHYDAAILFTREDLCGHHSCDTLGMADVGTICSPERSCAVIEDDGLH  
AAFTVAHEIGHLLGLSHDDSKFCEENFGSTEDKRLMSSILTSIDASKPWSKCTSATITEFLDDGHGNCLLDVPRKQILGP  
EELPGQTYDATQQCNLTFGPEYSVCPGMDVLCARLWCAVVRQGMVCLTKKLPAVEGTPCGKGRIQLQKCVDKTKKKYYS  
TSSHGNGSWGWPWGQCSRSCGGGVQFAYRHCNNPAPRNSGRYCTGKRAIYRSCSVIPCPNGKSFHEQCEAKNGVQSDA  
KGVKTFVEWPKYAGVLPADVCKLTCRAKGTGYVVFSPKVTGTECRPYSNSVVRGRCVRTGCDGIIGSKLQYDKCGV  
CGGDNSSCTKIIGTFNKKSKGYTDVVRIPGATHIKVRQFKAXDQTRFTAYLALKKKTGEYLINGKYMISTSETIIDING  
TVMNYSWWSHRDDFLHGMGYSATKEILIVQILATDPTKALDVRYSFVVPKTTQKVNCSGPDPLVLERP

*Fig. 4*

5/39

KIAA0605 Accession #: AB011177

cactggcggg	gaaaatcccc	tctctttttt	tctctctctt	ttttcttttt	tgagacggaa	60
tctcactctt	tcacccagac	tggagggcag	cggcgagatc	tcggctcact	gcaacctcca	120
cctcccaggt	tcaagcaatt	ctcctgcctc	agccttccga	gtagctggga	ttacaggtgc	180
ccgccaccac	gcccgactaa	tttttgtatt	tttagtagag	acaggatttt	accatgttgg	240
ccatgttgtt	ctcaaaactc	tgacctcgtg	tgatccccc	gcttcagcct	ctcaaaactgc	300
tgggattata	ggcatgagcc	actgcgcctg	gccaacaatc	cccttctaaa	ggcaggttgt	360
gtctccagca	ccagggccat	acggctgcaa	cacccctaca	agtgccgggt	ctgccagaca	420
accacgacca	actagtcaca	gataaccttg	aggcctgggc	actggctggg	ccccgagggc	480
tcttcccaaa	gcgtaccctg	gtcatctgga	agaggatcgg	agctggcctg	gtggtgacag	540
tggccttgc	tcctaggatg	gatggcagat	ggcaatgttc	ctgctggccc	tggctctcgc	600
tgggttcggc	agttgtagct	ggggacacag	tgtcaaccgg	gtccacggac	aacagcccaa	660
catccaatag	cctggagggg	ggcaccgacg	ccacggcctt	ctggtggggg	gagtggacca	720
agtggacggc	gttttccccc	agttgcgggg	gtggggtgac	atcccaggag	cggcactgcc	780
tgcagcagag	gaggaaagtc	gtcccggggc	ccgggaacag	gacctgcacg	ggcacgtcca	840
agcggtagca	gctctgcaga	gtgcaggagt	gtccgccgga	cgggagagag	ttccgcgagg	900
agcagtgcgt	ctccttcaac	tcccacgtgt	acaacgggcg	gacgcaccag	tggaagcctc	960
tgtacccgga	tgactatgtc	cacatctcca	gcaaaccgtg	tgacctgcac	tgtaccaccg	1020
tggacggcca	gcggcagctc	atggtccccg	cccgcgacgg	cacatcctgc	aagctcactg	1080
acctgcgagg	ggtttgcgtg	tctggaaaat	gtgagcccat	cggctgtgac	gggtgtcttt	1140
tctccaccca	cacactggac	aagtgtggca	tctgccaggg	ggacggtagc	agctgcaccc	1200
acgtgacggg	caactatcgc	aaggggaatg	cccaccttgg	ttactctctg	gtgaccacaa	1260
tcccggctgt	tggccgagac	atccagattg	tagagaggaa	gaagtccgct	gacgtgctag	1320
ctcttgacga	tgaagctggc	tactacttct	tcaacggcaa	ctacaagggt	gacagcccca	1380
agaacticaa	catcgctggc	acggttgtca	agtaccggcg	gcccattggt	gtctatgaga	1440
ccggaatcga	gtacatcgig	gcacaggggc	ccaccaacca	gggcctgaat	gtcatggtgt	1500
ggaaccagaa	cggcaaaagc	ccctccatca	ccttcgagta	cacgctgctg	cagccggcac	1560
acgagagccg	ccccagccc	atctactatg	gcttctccga	gagcgtctag	agccaggggc	1620
tggacggggc	cgggctgatg	ggcttcatcc	cgacaacgg	ctccctctac	ggccaggcct	1680
cctcagagcg	gctgggcctg	gacaaccggc	tgctcgccca	cccgggcctg	gacatggagc	1740
tgggccccag	ccaggggcag	gagaccaacg	aggtgtgcga	gcaggccggc	ggcggggcct	1800
gcgagggggc	ccccaggggc	aagggtcttc	gagaccgcaa	cgtcacgggg	actcctctca	1860
ccggggacaa	ggatgacgaa	gaggttgaca	cccacttcgc	ctcccaggag	ttcttctcgg	1920
ctaaccgcat	ctctgaccag	ctgctggggc	caggctctga	cttgaaggac	ttcacctcca	1980
atgagactgt	gaacagcatc	tttgacaggg	gcgccccaa	gagctccctg	gccgagagct	2040
tcttcgtgga	ttatgaggag	aacgaggggg	ctggccctta	cctgctcaac	gggtcctacc	2100
tggagctgag	cagcgacagg	gttgccaaca	gtcctccga	ggccccattc	cccaacgtta	2160
gcaccagcct	gtcacctcgc	gccgggaaca	ggactcacia	ggccaggacc	aggcccaagg	2220
cgcgcaagca	aggcgtgagt	cccgcggaca	tgtaccgggt	gaagctctcg	tcccacgagc	2280
cctgcagtgc	cacctgcacc	acagggggtca	tgtctgcgta	cggcatgtgt	gtccgctatg	2340
atggcgctga	ggtggatgac	agctactgtg	acgccctgac	ccgtcccag	cctgtccacg	2400
agttctgcgc	tgggagggag	tgccagccca	ggtgggagac	gagcagctgg	agcgagtgtt	2460

*Fig. 5A*

6/39

cgcgcacctg cggagaggcc taccagtcc gcgtcgtcgc ctgctggaag atgctctcgc 2520  
 ccggcttcga cagctccgtg tacagcgacc tgtcgcaggc agccgaggcc gtgcggcccg 2580  
 aggaacgcaa gacctgccg aaccccgct gcgggcccc gtgggagatg tcggagtgtg 2640  
 ccgagtgcac tgccaagtgt ggggagcgca gtgtgtgac caggacatc cgtgctcgg 2700  
 aggatgagaa gctgtgtgac cccaacacca ggctgtagg ggagaagaac tgcacgggcc 2760  
 cgccctgtga cggcagtg accgtctccg actggggacc gtgcagtga agctgcgggc 2820  
 aaggccgcac catcaggcac gtgtactgca agaccagcga cggacggga gtacctgagt 2880  
 cccagtgcga gatggagacc aagcctctgg ccattccacc ctgtggggac aaaaactgtc 2940  
 ccgcccactg gctggcccag gactgggagc ggtgcaaac cactgcggg cgcgggtca 3000  
 agaagcggt ggtgctctgc atggagctgg ccaacggaa gccgcagacg cgcagtggcc 3060  
 ccgagtgcgg gctcgccaag aagcctccg aggagagcac gtgtttcgag aggcctgct 3120  
 tcaagtggta caccagcccc tggtcagagt gcaccaagac ctgcggggtg ggcgtgagga 3180  
 tgcgagacgt caagtgtac caggggaccg acatcgtccg tggttgcgat ccgttggtga 3240  
 agcccgttg cagacaggcc tgtgatctgc agccctgcc caggagccc ccagatgaca 3300  
 gctgccagga ccagccaggc accaactgtg ccctggccat caaagtgaac cctgcgggc 3360  
 actggtacta cagcaaggcg tctgcccgt cctgcaggcc cccccactcc taggcccggc 3420  
 agctgcagcc cctccagat gaagaccaag cgcctcctt gggctgctg cagcttctgg 3480  
 ggcccccaca gacccccctc ctgcggggca cgtggccta agagacgtgg cactgagcct 3540  
 cggctgtcga gaggggactt cccacggccc gtggacctt gtgctcctg ggcagagcct 3600  
 ccggaccca gtggcctccc ccagacagag ccacccctgc cgtgggaacc tgtccgtgtt 3660  
 cctgcgtgga tccgtgttt gtggctccc cccccagcc cccagcagc cccagccga 3720  
 gggggccagg gccacagcc agcgggtgag gtgtcttgc ccgggccgt agcccagcc 3780  
 ctctctgggt ggcaggcct tctgaaggaa actgcaggc gagccaacg tgggtggggg 3840  
 cttctctccc tcagaggcca tggggtgaga ggggtcagg cagccaagga ggcccaggcg 3900  
 tgctccctct tatggagccc ctcccatgga gctctcttcc cgccgcaatt tctaccccg 3960  
 gcagaggcgc ttgccacgg gacgtttgg gatggacctt ggcgccgcc cctgcagtca 4020  
 gcgtcagtgc tcatctacgt taataaagtg gtccattta tggcggc 4067

*Fig. 5B*

MDGRWQCSCHAWFLLVLAVVAGDVTSTGSDNSPTSNSLEGGTDAFWGWTWTAFSRSCGGVTSQERHCLQRRKSVPGPNRTCTGTSKRYQ  
 LCRVQECPPDGRSFREEQCVSFNSHVYNGRTHQWKPLYDDYVHISSKPCDLHCTTVDGQRQLMVPARDGTSCKLTDLRGVCVSGKCEPIGCGVLFS  
 THTLDKCGICQGDGSSCTHTVGNRYKGNHLYSLVTHIPAGARDIQUIVERKKSADVLALADEAGYFFNGNYKVDSKPNFNIAGTVVYRRPMDVYE  
 TGIEYIVAQPTNQGLNVMWNQNGKSPSITFEYTLQPPHESRPOIYYGFSESAESQGLDAGLMGFIHNGSLYGQASSERLGLDNRLFHHPGLD  
 MELGPSQGOETNEVCEQAGGACGPPRGKGFDRNVTGTPLTGDKDDEVDTHFASQEFFSANAI SDQLLGAGSDLKDFLTNETVNSIFAQAPRSS  
 LAESFFVDYEENEGAPYLLNGSYLELSSDRVANSSSEAPFPNVSTSLT SAGNRTHKARTRPKARKQGVSPADMYRWKLS SHEPCSATCTTGVM SAY  
 AMCVRYDGVYVDDSYCDALTRPEPVHEFCAGRECQPRWETSSWSECSRTCGEGYQFRVVRWKM LSPGFDSSVYSDLC EAAEAVRPEERKTCRN PACG  
 POWEMSEWSECTAKCGERSVVTDRIRCSDEKLCDPNTRPVGEKNCTGPPCDRQWTVSDWGPCSGSCGQGRITRHVYCKTSDGRVVPESQCOMETKPL  
 AIHPCGDKNCPAHWLAQDWERCNTTCGRGVKKRLVLCMELANGKPQTRSGPECGLAKKPEESTCFERPCFKWYTS PWSECTKTCGVGVRMRDVKCYQ  
 GTDIVRGCDPLVKPVGRQACDLQPCPTEPPDDSCDQDQPGTNCALAIKVNLCGHWYYSKACCRSCRPPHS (951 amino acids)

*Fig. 6*

SUBSTITUTE SHEET (RULE 26)



7/39

DNA sequence of metalloproteinase gene (KIAA0366) Accession #: AB002364

```

gtcactttg ttgatagcag ccgctctggt agaggttagg acttcagctg atggacaagc   60
tggtaatgaa gaaatggtgc aaatagattt accaataaag agatatagag agtatgagct   120
ggtgactcca gtcagcacaa atctagaagg acgctatctc tccatactc tttctgagag   180
tcacaaaaag aggtcagcga gggacgtgtc ttccaacctt gagcagttgt tctttaacat   240
cacggcattt ggaaaagatt ttcattctgc actaaagccc aacactcaac tagtagctcc   300
tggggtgttt gtggagtggc atgagacatc tctggtgcct ggaatataa ccgatcccat   360
taacaacat caaccaggaa gtgctacgta tagaatccgg aaaacagagc ctttgagac   420
taactgrgct tatgttggg acatcgtgga cattccagga acctctgtt ccacagcaa   480
ctgtgatggt ctggctggaa tgataaaaag tgataatgaa gagtatttca ttgaacctt   540
ggaaagaggt aaacagatgg aggaagaaaa aggaaggatt catgttgtct acaagagatc   600
agctgtagaa caggctccca tagacatgtc caaagacttc cactacagag agtcggacct   660
ggaaggcctt gatgatctag gtactgttta tggcaacatc caccagcagc tgaatgaaac   720
aatgagacgc cgcagacacg cgggagaaaa cgattacaat atcgaggtac tgctgggagt   780
ggatgactct gtgtccgtt tccatggcaa agagcacgtc caaaactacc tcccgacct   840
aatgaacatt gtgaatgaaa ttaccatga tgagtcctc ggagtcata taaatgtggt   900
cctggtgcgc atgataatgc tgggatatgc aaagtccatc agcctcatag aaaggggaaa   960
cccattccga agcttgaga atgtgtgtc ctggcgctcc caacagcaaa gatctgatct  1020
caaccactct gaaccatg accatgcaat tttttaacc aggcagact ttggacctgc  1080
tggaatgcaa ggatagtctc cagtcaccgg catgtgtcat ccagtgaaga gttgtacct  1140
gaatcatgag gatggtttt catctgctt ttagtagcc catgaacgg gccatgtgtt  1200
gggaatggag catgatggac aaggcaacag gtgtggtgat gagactgcta tgggaagtgt  1260
catggctccc ttgtacaag cagcattcca tcgttaccac tggctccgat gcagtgttca  1320
agaactgaaa agatataatc attcctatga ctgtctcctt gatgacctt ttgatcatga  1380
ttggcctaaa ctcccagaac ttcttgaat caattattct atggatgagc aatgtcgtt  1440
tgattttggt gttggctata aaatgtgcac cgcgttccga acctttgacc catgtaaca  1500
gctgtggtgt agccatcctg ataacccta cttttgtaag actaaaagg gacctccact  1560
tgatgggact gaatgtgctg ctggaatatg gtgtataag ggtcattgca tgtggaagaa  1620
tgctaactag caaaaacaag atggcaattg ggggtcatgg actaaattg gctcctgttc  1680
tcggacatgt ggaactggtg ttcttttcag aacacgccag tgcaataatc ccattgccat  1740
caatggtggt caggattgtc ctggtgttaa ttttgagtac cagctttgta acacagaaga  1800
atgccaaaaa cactttgagg acttcagagc acagcagtg cagcagcga actcccactt  1860
tgaataccag aataccaaac accactggtt gccatatgaa catcctgacc ccaagaaaag  1920
atgccacctt tactgtcagt ccaaggagac tggagatgtt gcttacatga aacaactggt  1980
gcatgatgga acgcactgtt cttacaaaga tccatatagc atatgtgtgc gaggagagt  2040
tgtgaaagtg ggcgtgata aagaaattgg ttctaataag gttgaggata agtgtggtgt  2100
ctgtggagga gataattccc actgccgaac cgtgaagggg acatttacca gaactccag  2160
gaagcttggg taccttaaga tgtttgatat acccctggg gctagacatg tgtaatacca  2220
agaagacgag gcttctctc atattctgc tattaagaac caggctacag gccattatat  2280
tttaaatggc aaaggggagg aagccaaatc gcggacctt atagatctt gtgtggagt  2340
ggattataac attgaagatg acattgaaag tcttcacacc gatggacctt tacatgatcc  2400
tgttattgtt ttgattatac ctcaagaaaa tgataccgc ttagcctga catataagta  2460
catcatccat gaagactctg tacctacaat caacagcaac aatgtcatcc aggaagaatt  2520

```

*Fig. 7A*

8/39

agatactttt	gagtgggctt	tgaagagctg	gtctcaggtt	tccaaacctt	gtggtggagg	2580
tttccagtag	actaaatatg	gatgccgtag	gaaaagtgat	aataaaatgg	tccatcgtag	2640
cttctgtgag	gccaaacaaa	agccgaaacc	tattagacga	atgtgcaata	ttcaagagtg	2700
tacacatcca	ctctgggtag	cagaagaatg	ggaacactgc	acaaaaacct	gtggaagttc	2760
tggctatcag	cttcgcactg	tacgctgcct	tcagccactc	cttgatggca	ccaaccgctc	2820
tgtgcacagc	aaatactgca	tgggtgaccg	tcccagagagc	cgccggccct	gtaacagagt	2880
gccctgccct	gcacagtggg	aaacaggacc	ctggagttag	tgttcagtga	cctgcggtga	2940
aggaacggag	gtgaggcagg	tcctctgcag	ggctggggac	cactgtgarg	gtgaaaagcc	3000
tgaagtcggc	agagcctgac	aactgcctcc	ttgtaatgat	gaaccatgtt	tgggagacaa	3060
gtccatattc	tgtcaaatgg	aagtggtggc	acgatactgc	tccataccag	gttataacaa	3120
gttatgttgt	gagtcctgca	gcaagcgcag	tagcaccctg	ccaccacat	accttctaga	3180
agctgctgaa	actcatgarg	atgtcatctc	taaccctagt	gacctcccta	gatctctagt	3240
gatgcttaca	tcittggttc	cttatcattc	agagacccct	gcaagaaga	tgtctttgag	3300
tagcatctct	tcagtgggag	gtccaaatgc	atatgtctgt	ttcaggccaa	acagtaaacc	3360
tgaatgtgct	aatttacgcc	agaggagtgc	tcagcaagca	ggaagtaaga	ctgtgagact	3420
ggtcaccgta	ccatccctcc	caccaccaa	gagggccac	ctcagttcag	cttcacaaat	3480
ggctgctgct	tccttctttg	cagccagtga	ttcaataggt	gcttctctc	aggcaagaac	3540
ctcaaagaaa	gatggaagaa	tcattgacaa	cagacgtccg	acaagatcat	ccaccttaga	3600
aagatgagaa	agtgaaccaa	aaaggctaga	aaccagagga	aaacctggac	aacctctctc	3660
ttcccatggt	gcatactgct	gtttaaagtg	gaaatctcta	tagatcgta	gctcatttta	3720
tctgtaattg	gaagaacaga	aagtgtctgc	tcactttcta	gttgctttca	tcctcctttt	3780
gttctgcatt	gactcattta	ccagaattca	ttggaagaaa	tcaccaaaga	ttattacaaa	3840
agaaaaatat	gttgctaaga	ttgtgttggt	cgctctctga	agcagaaaag	ggactggaac	3900
caattgtgca	tatcagctga	ctttttgttt	gttttagaaa	agttacagta	aaaattaaaa	3960
agagatacca	atggtttaca	ctttaacaag	aaattttgga	tatggaacaa	agaattctta	4020
gactgttatt	cctatttacc	tatattagaa	atatgtatg	agcaaatgtg	cagctgttgt	4080
gtaaatactg	tatattgcaa	aaatcagtat	tattttaaga	gatgtgttct	caaatgattg	4140
tttactatat	tacatttctg	gatgttctag	gtgcctgtcg	ttgagtattg	ccttggttga	4200
cattctatag	gttaattttc	aaagcagagt	attacaaaag	agaagttaga	attacagcta	4260
ctgacaatat	aaagggtttt	gttgaatcaa	caatgtgata	cgtaaattat	agaaaaagaa	4320
aagaaacaca	aaagctatag	atatacagat	atcagcttac	ctattgcctt	ctatacttat	4380
aatttaaaag	attggtgtct	tagtacactt	gtggtcacag	ggatcaacga	atagtaaaata	4440
atgaactcgt	gcaagacaaa	actgaaaccc	tctttccagg	acctcagtag	gcaccgttga	4500
gggtgccttt	gtttttgtgt	gtgtgtgttc	tttttaatt	ttcgatttgt	tgacagatac	4560
aaacagttat	actcaatgta	ctgtaataat	cgcaaaggaa	aaagtgttgg	gataacttat	4620
ttgtatgttg	gtagctgaga	aaaaatcat	cagtctagaa	ttgatatttg	agtatagtag	4680
agctttgggg	ctttgaaggc	aggttcaaga	aagcatatgt	cgatggttga	gatattttatt	4740
ttccatatgg	ttcatgttca	aatgttcaca	accacaatgc	atctgactgc	aataatgtgc	4800
taataattta	tgtcagtagt	caccttgctc	acagcaaaagc	cagaatgct	ctctccaggg	4860
agtagatgta	aagtacttgt	acatagaatt	cagaactgaa	gatattttatt	aaaagttgat	4920
tttttttct	tgatagtatt	tttatgtact	aaatatttac	actaatatca	attacatatt	4980
ttggtaaact	agagagacat	aattagagat	gcattgcttg	ttctgtgcat	agagaccttt	5040
aagcaaaact	ctacagccaa	ctcaaaagct	aaaactgaac	aaatttgatg	ttatgcaaac	5100
atcttgcat	tttagtagtt	gatattaagt	tgatgacttg	tttcccttca	aggaacacatt	5160

*Fig. 7B*

9/39

aaattgtag gactcagcta gctgttcaat gaaattgtga attagaaaca tttttaaaag 5220  
 tttttgaaag agataagtgc atcatgaatt acatgtacat gagaggagat agtgatatca 5280  
 gcataatgat tttaggtca gtacctgagc tgtctaaaaa tatattatac aaactaaaat 5340  
 gtagatgaat taacctctca aagcacagaa tgtgcaagaa cttttgcatt ttaatcgttg 5400  
 taaactaaca gcttaaaacta ttgactctat acctctaaag aattgtgct actttgtgca 5460  
 agaactttga aggtcaaatt aggcataatc cagatagtaa aacaatccct aagccttaag 5520  
 tcttttttt ttctaaaaa tccccataga ataaaattct ctctagtta cttgtgtgtg 5580  
 catacatctc atccacaggg gaagataaag atggtcacac aaacagtttc cataaagatg 5640  
 tacatatcca ttatacttct gacctttggg ctttcttttc tactaagcta aaaattcctt 5700  
 tttatcaaag tgcactactc tgatgctgtt tgggtgactg agagcacgta ccaataaaaa 5760  
 tgtaacaaa atai 5774

*Fig. 7C*

1  
 slwliaaalvevrtsadggagneenvqidlpikryreyelvtpvstnlegrylshtlsashkkrsardvssnpeqlffni  
 80  
 tafgkdfhlrlkntqlvapgavvewhetslvpgnitdpinnhqgsatyriktelqtncayvgdivdipgtsvaisn  
 cdglagmiksneeyfieplergkmeekgrihvvykrsaveqapidmskdfhyresdlegldlgtvygnihqqlnet  
 mrrrrhagendynievlvgvddsvvrfhgkehvnlylltlnnivneiyhdeslgvhinvvlvrminlgysisliern  
 psrslenvcrwasqqrsdlnhsehhdhai fltrqdfgpagmqgyapvtgmchpvrsc lnhedgfssa fvvahetghvl  
 gmehdgggnrcgdetamgsvmapl vqaa fhryhwsrscgqelkryihsydc lldpfdhdwplpelpginysmdeqcrf  
 dfvgvykmctaftrfdpckqlwchshpdpnfcktkkppldgtecaagkwcykghcmwnanqqkqdgngswtkfgscs  
 rtcgtgvrftrqcnmpingggdcpgvnfeyqlcnteecqkhfedfraqqcqrnshfeyqntkhhwlpvehdpkkr  
 chlycqscketgdvaymkqlvhdgtchsykdpysicvrgecvkvgcdkeigsnkvedkcgvcggdnshcrtvkgfttrtp  
 klgyikmf dipparhvlqedeasphilaiknqatghylngkgeeaksrftidlgvewdyniedieslhtdgp lhd  
 vivliipqendrssltykyihedsuptinsnnviqueeldtfewalkswsqvskpcgggfytkygcrrksdnkmvhrs  
 fceankpkpirrmcniqecthplwvaeewehctktcgssgyqlrtvrc lqplldgtnrsvhskycmgrpesrrpcnr  
 pcpaqwktpwsecsvtcegevevrqlcragdhcdgekpesvracqlppcndepc lgdksifcmevlarycsipgynk  
 lccescskrsstlpppyl leaaethddvisnpsdlprslvmpts lvyhsetpakkms lssissvggnayaafrpnspk  
 dganlqrsaqqagsktvrlvtvpsspptkrvhlssasqmaasffaasdsigassqartskkdkkiidnrrptsstle  
 r (1,201)

*Fig. 8*

10/39

GGAATTTCGGGCCGCGTCGACGTCAATACCAACTCCGAGCACACGGCCGTCATCAGCCTCTGCTCAGGAATGCTGGGCAC  
ATTCCGGTCTCATGATGGGGATTATTTTATTGAACCTACAGTCTATGGATGAACAAGAAGATGAAGAGGAACAAAACA  
AACCCACATCATTTATAGGCGCAGCGCCCCCAGAGAGAGCCCTCAACAGGAAGGCATGCATGTGACACCTCAGAACAC  
AAAAATAGGCACAGTAAAGACAAGAAGAAAACAGAGCAAGAAAATGGGAGAAAAGGATTAACCTGGCTGGTGACGTAGC  
AGCATTAAACAGCGGCTTAGCAACAGAGGCATTTTCTGCTTATGGTAATAAGACGGACAACACAAGAGAAAAGAGGACCC  
ACAGAAGGACAAAACGTTTTTATCCTATCCACGTTTGTAGAAGTCTTGGTGGTGACAGACAACAGAATGGTTTCATAC  
CATGGAGAAAACCTTCAACACTATATTTTAACTTTAATGTCAATTGATGGCCTTCCATATCTTTAATGCTCAGACAAC  
ATTA AAAAACCTTTGCCAGTGGCAGCATTGGAAGAAGTCCAGGTGGAATCCATCATGATACTGCTGTTCTCTTAACAA  
GACAGGATATCTGCAGAGCTCAGACAATGTGATACCTTAGGCCTGGCTGAAGTGGGAACCATTTGTGATCCCTATAGA  
AGCTGTTCTATTAGTGAAGATAGTGGATTGAGTACAGCTTTTACGATCGCCCATGAGCTGGGCCATGTGTTTAAATGCC  
TCATGATGACAACAACAAATGTAAGAAGAAGGAGTTAAGAGTCCCCAGCATGTCATGGCTCCAACACTGAACCTCTACA  
CCAACCCCTGGATGTGGTCAAAGTGTAGTCGAAAATATATCACTGAGTTTTTAGACACTGGTTATGGCGAGTGTGCTT  
AACGAACCTGAATCCAGACCTACCTTTGCCTGTCCAAGTCCAGGCATCCTTTACAACGTGAATAAACAATGTGAATT  
GATTTTGGACAGGTTCTCAGGTGTGCCATATATGATGCAGTGCAGACGGCTCTGGTGCAATAACGTCAATGGAGTAC  
ACAAAGGCTGCCGACTCAGCACACACCTGGGCCGATGGGACGGAGTGCAGCCTGGAAGCACTGCAAGTATGGATTT  
TGTGTTCCAAAGAAATGGATGTCCCGTGACAGATGGATCTGGGGAAGTGGAGTCCCTTTGGAACCTGCTCCAGAAC  
ATGTGGAGGGGCATCAAAACAGCCATTCGAGAGTGCAACAGACCAGAACCAAAAATGGTGGAAAATACTGTGTAGGAC  
GTAGAATGAAATTTAAGTCTGCAACACGGAGCCATGTCTCAAGCAGAAGCGAGACTTCCGAGATGAACAGTGTGCTCAC  
TTTGACGGGAAGCATTTTAAATCAACGGTCTGCTTCCCAATGTGCGCTGGGTCCCTAAATACAGTGGAAATTCGATGAA  
GGACCGGTGCAAGTTGTTCTGCAGAGTGGCAGGGAACACAGCCTACTATCAGCTTCGAGACAGAGTGATAGATGGAACCTC  
CTTGTTGCCAGGACACAAATGATATCTGTGTCCAGGGCTTTGCCGGCAAGCTGGATGCGATCATGTTTTAACTCAAAA  
GCCCCGAGAGATAAATGTGGGTTTGTGGTGGCGATAATCTTCATGCAAAACAGTGGCAGGAACATTTAATACAGTACA  
TTATGGTTACAATACTGTGGTCCGAATTCAGCTGGTGCTACCAATATTGATGTGCGGCAGCACAGTTTCTCAGGGGAAA  
CAGACGATGACAACCTTAGCTTTATCAAGCAGTAAAGGTGAATCTTGCTAAATGGAACCTTTGTTGTACAATGGCC  
AAAAGGGAAATTCGATTGGGAATGCTGTGGTAGAGTACAGTGGGTCCGAGACTGCCGTAGAAAGAATTAACCTCAACAGA  
TCGCATTGAGCAAGAACTTTTGTTCAGGTTTTGTCGGTGGGAAAGTTGTACAACCCGATGTACGCTATTCTTTCAATA  
TTCCAATTGAAGATAAACCTCAGCAGTTTTACTGGAACAGTCAATGGCCATGGCAAGCATGCAGTAAACCCTGCCAAGGG  
GAACGGAAACGAAAACCTGTTTGCACCAGGGAATCTGATCAGCTTACTGTTTCTGATCAAAGATGCGATCGGCTGCCCCA  
GCCTGGACACATTACTGAACCTGTGGTACAGACTGTGACCTGAGGTGGCATGTTGCCAGCAGGAGTGAATGTAGTGCCC

*Fig. 9A*

SUBSTITUTE SHEET (RULE 26)

11/39

AGTGTGGCTTGGGTTACCGCACATTGGACATCTACTGTGCCAAATATAGCAGGCTGGATGGGAAGACTGAGAAGGTTGAT  
 GATGGTTTTTGCAGCAGCCATCCCAAACCAAGCAACCGTGAAAAATGCTCAGGGGAATGTAACACGGGTGGCTGGCGCTA  
 TTCTGCCTGGACTGAATGTTCAAAAAGCTGTGACGGTGGGACCCAGAGGAGAAGGGCTATTTGTGTCAATACCCGAAATG  
 ATGTACTGGATGACAGCAAATGCACACATCAAGAGAAAGTTACCATTAGAGGTGCAGTGAGTTCCTTGTCCACAGTGG  
 AAATCTGGAGACTGGTCAGAGTGCTTGGTCACCTGTGGAAAAGGGCATAAGCACCGCCAGGCTGGTGTGAGTTTGGTGA  
 AGATCGATTAAATGATAGAATGTGTGACCCAGAGGTGCAGCGGGCCGGAATTCGCCGATACTGACGGGCTCCAGGAGT  
 CGTCGCCACCAATCCCATATGGAACCGTCGATATTCAGCCATGTGCCTTCAAGCCGAATTCAG

*Fig. 9B*

GIRGRVDVNTNSEHTAVISLCSGMLGTFRSHDGDYFIEPLQSMDEQEDEEQNKPHIIYRRSAPQREPSTGRHACDTSEH  
 KNRHSDKKKTRARKWGERINLAGDVAALNSGLATEAFSAYGNKTDNTREKRTHRRTKRFLSYPRFVEVLVADNRMVSY  
 HGENLQHYILTLMSIDGPSISFNAQTTLKNLCQWQHSKNSPGGIHHDTAVLLTRQDICRAHDKCDTLGLAELGTICDPYR  
 SCSISEDSGLSTAFTIAHELGHVFNMPHDDNNKCKEEGVKSPQHVMAPTLNFYTNPMWSKSRKYITEFLDTGYGECLL  
 NEPESRPYPLPVQLPGILYNVNKQCELIFGPGSQVCPYMMQCRRLWCNNVNGVHKGCRTQHTPWADGTECEPGKHCKYGF  
 CVPKEMDVPVTDGWSWSWSPFGTCSRTCGGGIKTAIRECNRPKNGGKYCVGRRMKFKSCNTEPCLKQKRDFRDEQCAH  
 FDGKHFNINGLLPNVRWVPKYSILMKDRCKLFCRVAGNTAYYQLRDRVIDGTGCGQDTNDICVQGLCRQAGCDHVLNSK  
 ARRDKCGVCGDNSSCKTVAGTFNTVHYGYNTVVRIPAGATNIDVRQHSFSGETDDNYLALSSSKGEFLNNGNFVVTMA  
 KREIRIGNAVVEYSGSETAVERINSTDRIEQELLQVLVSGKLYNPVRYSFNIPIEDKPOQFYWNHGPWQACSKPCQG  
 ERKRKLVTRESQDLTVSDQRCRLPQPGHITEPCGTDCLRWHVASRSECSAQCGLYRTLDIYCAKYSRLDGKTEKVD  
 DGFCSHPKPSNREKCSGECNTGGWRYSAWTECSKSCDGGTQRRRAICVNTRNDVLDDSKCTHQEKVTIQRCEFPQPW  
 KSGDWSECLVTCGKGHKHRQVWCQFGEDRLNDRMCDPEVDAANSAOTDGLQESSPPIPIWKPSIFSHVPSSRIP

*Fig. 10*

12/39

cacatatgcacgagagagacagaggaggaaagagacagagacaaaggcacagcggaagaaggcagagacagggcaggcac  
 agaagcgccccagacagagtcttacagaggagagggcagagaaagctgcagaagacacaggcaggagagacaaagatcc  
 aggaagaggaggctcaggaggagagtgttgagaagccagaccctgggcacctctcccaagcccaaggactaagtgttct  
 ccatttcctttaacggctcctcagcccttctgaaaactttgctctgaccttggcaggagtccaagccccaggctacaga  
 gaggagctttccaaagctaggggtgtggaggacttggcgccctagacggcctcagtcctcccagctgcagtaccagtgcc  
 atgtcccagacaggctcgcacccgggaggggcttggcagggcgctggctgtggggagcccaacctgcctcctgctccc  
 cattgtgccgctctcctggctgggtgtggctgcttctgctactgctggcctctctcctgccctcagccggctggccagcc  
 cctccccgggaggaggagatcggtgttccagagaagctcaacggcagcgtcctgcctggctcgggcacccctgccagg  
 ctgtgtgccgcttgcaggcctttggggagacgctgctactagagctggagcaggactccggtgtgcaggtcgaggggct  
 gacagtgcagtacctgggccaggcgctgagctgctgggtggagcagagcctggcacctacctgactggcaccatcaatg  
 gagatccggagtcggtggcatctctgcactgggatgggggagccctgttaggcgtgttacaatatcggggggctgaactc  
 cacctccagccctggaggaggcacccttaactctgctgggggacctggggctcacatcctacgccggaagagtcctgc  
 cagcggctcaaggtcccatgtgcaacgtcaaggctcctcttggaaagccccagccccagaccgaagagccaagcgctttg  
 ctactgtagtagattgtggagacactggtggtggcagatgacaagatggccgattccacgggtcggggctaaagcgc  
 tactgttaacagtgtggcagcagcagccaaggccttaagcacccaagcatccgcaatcctgtcagcttgggtggac  
 tcggctagtgtatcctggggtcaggcaggagggggcccaagtggggccagtgctgcccagaccctgcgcagcttctgtg  
 cctggcagcggggcctaacacccctgaggactcggaccctgaccactttgacacagccattctgtttaccgctcaggac  
 ctgtgtggagtctccacttgcgacacgctgggtatggctgagtgggcaccgtctgtgaccggctcggagctgtgccat  
 tgtggaggatgatgggtccagtcagccttcaactgctgctcatgaactgggtcatgtcttaacatgctccatgacaact  
 ccaagccatgcatcagtttgaatgggcctttgagcacctctcgccatgtcatggccctgtgatggctcatgtggatcct  
 gaggagccctggtccccctgcagtccccgttcatcactgacttccctggacaatggctatgggactgtctcttagacaa  
 accagaggctccattgcatctgcctgtgactttccctggcaaggactatgatgtgaccgccagtgccagctgaccttcg  
 ggcccgaactcacgccattgtccacagctgcccggccctgtgctgccctctggtgctctggccacctcaatggccatgcc  
 atgtgccagaccaaactcgccttggccgatggcacaccttgcggggccgcagggcctgcatgggtggctcgtgcct  
 ccacatggaccagctccaggacttcaatatccacaggctggtggctggggtccttggggaccatggggtgactgctctc  
 ggacctgtgggggtggtgtccagttctcctcccagactgcacgaggcctgtccccggaatggtggcaagtactgtgag  
 ggccgctgacctgctcctgctcctgcaacactgaggactgccaactggctcagccctgaccttccgcgaggagcagtg  
 tgctgctacaaccaccgcaccgacctctcaagagcttcccagggcccatggactgggttctctgctacacaggcgtgg  
 cccccaggaccagtgc aaactcacctgccaggccccggcactgggctactactatgtgctggagccacgggtggttagat

*Fig. 11A*

13/39

gggaccccctgttccccggacagctcctcggctgtgtccagggccgatgcatccatgctggctgtgatcgcatcattgg  
ctccaagaagaagtttgacaagtgcattggtgtcggaggggacggttctggttcagcaagcagtcaggctccttcagga  
aattcaggtacggatacaacaatgtggtcactatccccgcggggccaccacattcttgcggcagcagggaaaccct  
ggccaccggagcatctacttggccctgaagctgccagatggctcctatgccctcaatggtgaatacacgctgatgccctc  
ccccacagatgtggtactgcctggggcagtcagcttgcgtacagcggggccactgcagcctcagagacactgtcaggcc  
atggggcactggcccagcctttgacactgcaagtcctagtggctggcaacccccaggacacacgcctccgatacagcttc  
ttcgtgccccggccgaccccttcaacgccacgccccactccccaggactggctgcaccgaagagcagattctggagat  
ccttcggcggcggccctggggggcaggaaataacctcactatccccgctgccctttctgggcaccggggcctcggactt  
agctgggagaaagagagagcttctgttgcctcatgctaagactcagtgaggaggggctgtggcgtagacactgccc  
ctcctctctgccctaatgcgcaggctggccctgccctggttctgccctgggaggcagtgatgggttagtggaaggaa  
gggtgacagacagccctccatctaaactgccccctgcctgcgggtcacaggagggagggggaaggcagggagggcc  
tgggccccagttgtattttatttagtattttattcactttttatttagcaccaggaaggggacaaggactagggctcctgggg  
aacctgacccctgacccctcatagccctcaccctggggctaggaaatccagggtggtggtgataggataagtgggtgtg  
gtatgcgtgtgtgtgtgtgtgaaatgtgtgtgtgtatgtatgaggtacaacctgttctgctttcctcttcttgaa  
ttttattttttgggaaaagaaaagtcagggttaggggtggcccttcaggagtgaggattatctttttttttttcttt  
ctttctttctttttttttttgagacagaatctcgctctgtcgcccaggctggagtgaatggcacaatctcggtcact  
gcatcctccgctcccgggttcaagtattctcatgcctcagcctcctgagtagctgggattacaggctcctgccaccac  
gcccagctaattttgtttgtttgtttggagacagagtcctcgctattgtcaccagggtggaatgatttcagctcact  
gcaaccttcgccacctgggttcagcaattctcctgcctcagcctcccagtagctgagattataggcacctaccaccac  
gcccggctaattttgtatttttagtagagacggggttcaccatgttgccaggctggtctcgaactcctgaccttagg  
tgatccactcgcttcatctcccaaagtgtgggattacaggcgtgagccaccgtgctggccacgcccactaattttt  
gtatttttagtagagacaggggttcaccatgttgccaggctgctctgaactcctgacctcaggtaatcgacctgcctc  
ggcctcccaaagtgtgggattacagggtgtgagccaccacggcggtacatattttttaattgaattctactatttatg  
tgatccttttgagtcagacagatgtggttgcatcctaactccatgtctctgagcattagatttctcatttgccaataat  
aatacctcccttagaagtttgtgtgaggattaaataatgtaaataaagaactagcataac

*Fig. 11B*

14/39

MSQTGSHPGRLAGRWLWGAQPCLLLPIVPLSWLVWLLLLLLASLLPSARLASPLPREEEIVFPEKLNQSVLPGSGTPAR  
LLCRLQAFGETLLLEEQDSGVQVEGLTVQYLGQAPPELLGGAEPGTYLGTINGDPESVASLHWDGGALLGVLYRGAEL  
HLQPLEGGTPNSAGGPGAHLRRKSPASGQGPCNVKAPLGSPSPRRRAKRFASLSRFVETLVVADDKMAAFHGAGLKR  
YLLTVMAAAAKAFKHPSIRNPVSLVVTRLVILSGGEEGPQVGPSAAQTLRSFCAWQRLNTPEDSDPHFDTAILFTRQD  
LCGVSTCDTLGMADVGTVCDPARSCAIVEDDGLQSAFTAHELGHVFNMLHDNSKPCISLNGPLSTSRHVMAVMAHVDP  
EEPWSPCSARFITDFLDNGYGHCLLDKPEAPLHLPVTFPGKDYDADRCQLTFGPDSRHCPQLPPPCAALWCSGHLNGHA  
MCQTKHSPWADGTPCGPAQACMGGRLHMDQLQDFNIPQAGGWGPWGPWGDCSRTC GGGVQFSSRDCTRPVPRNGGKYCE  
GRRTRFRSCNTEDCPTGSALTFREEQCAAYNHRTDLFKSFGPMDWVPRYTGVAPQDQCKLTCQARALGYYYVLEPRVVD  
GTPCSPDSSSVCVQGRCIHAGCDRIIGSKKKFDKCMVCGDGGSGCSKQSGSFRKFRYGYNVVTIPAGATHILVRQQGNP  
GHRSIYLALKLPDGSYALNGEYTLMPSPDVLPGAVSLRYSGATAAETLSGHGPLAQPLTLQVLVAGNPQDTRLRYSF  
FVPRPTPSTPRPTQDWLHRAQILEILRRRPWAGRK

*Fig. 12*



15/39

Rat ADAMTS 5 DNA

ACTCACTATA GGGCTCGAGC GGCCGCCCGG GCAGGTCAGA GGCTCACTGG CAGCTCTCTA	60
GACCTGCGAC GCTGCTTCTA TTCCGGGTAT GTGAACGCGG AGCCAGACTC CTTTGCTGCT	120
GTAAGCCTAT GCGGGGGTCT CCGCGGAGCC TTTGGCTACC AAGGTGCGGA GTATGTCATT	180
AGCCCTCTGC CCAACACCAG CGCGCTGAG GCGCAGCGTC ATAGCCAGGG CGCACACCTT	240
CTCCAGCGCC GGGGTGCTCC CGTAGGGCCT TCCGGAGACC CTACCTCTCG CTGCGGGGTG	300
GCCTCGGGCT GGAACCCCGC CATCCTGAGG GCCTTGGACC CTTATAAACC ACGGCGGACG	360
GGCGTGGGCG AAAGCCACAA CCGGCGCAGG TCTGGGCGCG CCAAGCGCTT CGTGTCTATA	420
CCACGGTACG TGGAGACACT GGTGGTGGCG GACGAGTCAA TGGTCAAGTT TCACGGCGCG	480
GATTTGGAAC ATTATCTGCT GACGCTGCTG GCCACGGCGG CGCGACTCTA CCGCCACCCC	540
AGCATCCTCA ACCCTATCAA CATCGTTGTG GTCAAGGTGT TACTCTTAGG AGATCGTGAC	600
ACTGGGCCCA AGGTCACAGG CAACGCGGCC CTGACTCTGC GCAACTTCTG TGCCTGGCAG	660
AAAAAGTTGA ACAAAGTGAG CGACAAGCAC CCCGAGTACT GGGACACAGC CATCCTCTTC	720
ACCAGACAGG ACCTATGCGG GGCTACCACC TGTGACACCT TGGGCATGGC TGATGTGGGC	780
ACCATGTGTG ATCCCAAGAG AAGCTGCTCT GTCATCGAGG ACGATGGGCT TCCGTCGGCC	840
TTCACCACTG CCCATGAGCT GGGCCATGTG TTCAACATGC CCCATGACAA CGTGAAGGTG	900
TGTGAGGAGG TGTTTGGGAA GCTCAGAGCC AACCACATGA TGTCTCCGAC ACTCATCCAG	960
ATCGACCGTG CCAACCCCTG GTCAGCCTGC AGTGCTGCCA TTATCACCGA CTTCTGGAC	1020
AGCGGGCAGG GTGACTGCCT CCTGGACCAG CCCAGCAAGC CCATCACCCCT GCCTGAGGAC	1080
CTGCCAGGCA CAAGCTACAG TTTGAGCCAA CAGTGCGAGC TGGCCTTTGG GGTGGGCTCT	1140
AAGCCCTGCC CATATATGCA GTACTGTACA AAGCTGTGGT GCACCGGCAA GGCCAAGGGG	1200
CAGATGGTGT GCCAGACTCG CCACTTCCCC TGGGCAGATG GCACCAGCTG TGGTGAGGGC	1260
AAGTTCTGCC TCAAGGGAGC CTGCGTGGAG AGACACAACC CAAACAAGTA CCGGGTGGAC	1320
GGCCCTTGGG CCAAGTGGGA GCCTTATGGT CCCTGCTCGC GCACCTGCGG TGGGGGCGCG	1380
CAGCTGGCCC GGAGGCAAGT GCAAGCAACC CTACCCCTGC CAACGGGCGG GAAGTACTGC	1440
GAGGGAGTGA GAGTGAAATA CCGATCTTGC AACTTGGAGC CCTGCCCCAG CTCAGCCTCT	1500
GGCAAGAGCT TCCGGGAA	1518

*Fig. 13*

16/39

THYRARAARAGQRLTGSSLDLRRCFYSGYVNAEPDSFAAVSLCGGLRGAFGYQGAIEYVISPLPNTSAPEAQRHSQGAHL  
 LQRRGAPVGPSPDPTSRGCVASGWNPAILRALDPYKPRRTGVGESHNRSSGRKRFVSI PRYVETLVVADESMVKFHGA  
 DLEHYLLTLLATAARLYRHPSILNPINIVVKVLLLDGDRDTGPKVTGNAALTLRNFCAWQKLNKVS DKHPEYWDTAILF  
 TRQDLGATTCDTLGMAVGTMCDPKRSCSVIEDDGLPSAFTTAHELGHVFNMPHDNVKVC EEVFGKLRANHMSPTLIQ  
 IDRANPWSACSAAIITDFLDSGHGDCLLDQPSKPIITLPEDLPGTSYLSQQCELAFGVGSKPCPYMQYCTKLWCTGKAKG  
 QMVCQTRHFPWADGTSCGEGKFCLKGACVERHNPKNYRVDGPWAKWEPYGPCSRTC GGGGAQLARRQVQATLPLPTGGKYC  
 EGV RVKYRSCNLEPCPSSASGKSFR

*Fig. 14*

GATGCATCTAAGCCCTGGTCCAAATGCACTTCAGCCACCATCACAGAATTCCTGGATGATGGCCATGGTAACTGTTTGCT  
 GGACCTACCACGAAAGCAGATCCTGGGCCCCGAAGAACTCCCAGGACAGACCTACGATGCCACCCAGCAGTGCAACCTTA  
 CATTGGGCTGAGTACTCCGTGTGTCCCGCATGGATGTCTGTGCTCCCCTGTGGTGTGCTGTGGTACGCCAGGGCCAG  
 ATGGTCTGTCTGACCAAGAAGCTTCTCGCGGTGGAAGGGACGCCTTGTGGAAGGGGAGAATCTGCCTGCAGGGCAAATG  
 TGTGGACAAAACCAAGAAAAAATATTATTCAACGTCAAGCCATGGCAACTGGGGATCTTGGGGATCCTGGGGCCAGTGTT  
 CTCGCTCATGTGGAGGAGGAGTGCAGTTGCCTATCGTCGTGTAATAACCTGTCTCCAGAAACAACGGACGCTACTGC  
 ACAGGGAAGAGGGCCATCTACCGCTCCTGCAGTCTCATGCCCTGCCACCCCAATGGTAAATCATTTCGTGATGAACAGTG  
 TGAGGCCAAAAATGGCTATCAGTCTGATGCAAAAGGAGTCAAAACTTTTGTGGAATGGGTCCCAAATATGCAAGTGTC  
 TGCCACGGATGTGTGCAAGCTGACCTGCAGAGCCAAAGGGACTGGCTACTATGTGGTATTTTCTCCAAAGGTGACCGAT  
 GGCACTGAATGTAGGCCGTACAGTAATTCGTCTGCGTCCGGGGGAAGTGTGTGAGAACTGGCTGTGACGGCATCATTGG  
 CTCAAAGCTGCAGTATGACAAGTGCGGAGTATGTGGAGGAGACAACCTCCAGCTGTACAAAGATTGTTGGAACCTTTAATA  
 AGAAAAGTAAGGGTTCANCTGACGTGGTGAGGATTCCTGAAGGGGCAACCCACATAAAAGTTCGACAGTTCAAAGCCAAA  
 GACCAGACTAGATTCACTGCCTATTTAGCCCTGAAAAAGAAAACGGTGAGTACCTTATCAATGGAAAGTACATGATCTC  
 CACTTCAGAGACTATCATTGACATCAATGGAACAGTCATGAACATAGCGGTTGGAGCCACAGGGATGACTTCCTGCATG  
 GCATGGGCTACTCTGCCACGAAGGAAATCTAATAGTGCAAGTCTTGCAACAGACCCCACTAAACCATTAGATGTCCGT  
 TATAGCTTTTTTGTTCCTCAAGAAGTCCACTCCAAAAGTAACTCTGTCACTAGTCATGGCAGCAATAAAGTGGGATCACA  
 CACTTCGAGCCCGCAGTGGGTACGGGCCCATGGCTCGCTGTCTAGGACCTGTGACACAGGTGGCACACCAGAACGG  
 TGCAGTGCCAGGATGGAACCGGAAGTTAGCAAAAGGATGTCTCTCTCCAAAGGCCCTTCTGCGTTTAAGCAATGCTTG  
 TTGAAGAAATGTTAG

*Fig. 15*

17/39

DASKPWSKCTSATITEFLDDGHGNCLLDLPRKQILGPEELPGQTYDATQQCNLTFGPEYSVCPGMDVCAPLWCAVVRQQQ  
MVCLTKKLPAVEGTPCGKGRIQLQKCVDTKKKYYSTSSHGNWGSWGSWGQCSRSCGGGVQFAYRRCNNPAPRNNGRYC  
TGKRAIYRSCSLMPCPPNGKSFRHEQCEAKNGYQSDAKGVKTFVEWVPKYASVLPDVCCLTCRAKGTGYVVVFSPKVTD  
GTECRPYSNSVCVRGKCVRTGCDGIIGSKLQYDKCGVCGGDNSSCTKIVGTFNKSKGSXDVVRIPEGATHIKVRQFKAK  
DQTRFTAYLALKKNGEYLINGKYMISTSETIIDINGTMNYSGWSHRDDFLHGMGYSATKEILIVQILATDPTKPLDVR  
YSFFVPKKSTPKVNSVTSHGSNKVGSHTSQPQWVTGPWLACSRCTDGTWHTRTVQCQDGNRKLAKGCPLSQRPSAFKQCL  
LKKC

*Fig. 16*

18/39

M - - - - -		Majority			
		10	20	30	40
1	M - - - - - G D V Q - R A A R S - - - - - R G S L S A H M L	mADAMTS-1			
1	- - - - -	hADAMTS-2			
1	- - G I R - - - - -	hADAMTS-3			
1	L L G A R Q Y R R N S G P P T P A P E T S I A N S K H P A R L S R A A P P G A Q	rADAMTS-4			
1	M - - - - - S Q T G S H P G R G L A G R - - - - W L W G A Q P C L L L	KIAA0688			
1	S L - - - - -	KIAA0366			
1	M D G R W Q C S - - - - -	KIAA0605			
- - - - - L L L L A L - T V L L S A D - - A G - P - - - E E E L		Majority			
		50	60	70	80
20	- - - - - L L L L A S I T M L L C A R G A H G R P T E E D E E L	mADAMTS-1			
1	- - - - -	hADAMTS-2			
4	- - - - -	hADAMTS-3			
41	R T M R L E W A S L L L L L L L C A S C L A L A A D N P A A A P A Q D K T R Q	rADAMTS-4			
27	P I V P L S W - - - L V W L L L L L L A S L L P S A R - - L A S P L P R E E E I	KIAA0688			
3	- - - - - W L I A A A L V E V R T S A D G Q A G N E E M V Q I D L	KIAA0366			
9	- - - - - C W A W F L L V L A V V A G D T V S T G S T D N S P T S N S L E G G T	KIAA0605			
V - - - - P - - - - - L R G - - - P - G - - G T T S R L -		Majority			
		90	100	110	120
47	V L - - - P S - - - - - L E R A - - - P - G H D S T T T R L -	mADAMTS-1			
1	- - - - -	hADAMTS-2			
4	- - - - -	hADAMTS-3			
81	P R - - - A A A A A A Q P D Q R Q W E E T Q E R G H L Q P L A R Q R R S S G L V	rADAMTS-4			
62	V F - - - P E - - - - - K L N G S V L P - G - S G T P A R L L	KIAA0688			
31	P I K R Y R E Y E L V T P V S T N L E G R Y L S H T L S A S H K K R S A R D V S	KIAA0366			
44	D A T A F W - - - - - W G E W T K W T A F S R S C G G G V T S Q E R	KIAA0605			
- N L D - - - - - G - - - - L - L E R D S G V - A P G - -		Majority			
		130	140	150	160
65	- R L D A F - - - - - G Q Q L H L K L Q P D S G F L A P G F T	mADAMTS-1			
1	- - - - -	hADAMTS-2			
4	- - - - - G R V D - - - - -	hADAMTS-3			
118	Q N I D Q L Y S G G G K V G Y L V Y A G G R R F L L D L E R D D T V G A A G G I	rADAMTS-4			
83	C R L Q A F - - - - - G E T L L L E L E Q D S G V Q V E G L T	KIAA0688			
71	S N P E Q L F - - - - - F N I T A F G K D F H L R L K P N T Q L V A P G A V	KIAA0366			
73	H C L Q - - - - - Q R R K S V P G P G - -	KIAA0605			

Fig. 17A